Method for natural strand sequencing of enriched genomic regions

By combining target polynucleotides with adaptors, tags, and solid supports, and integrating sequencing adaptors, the high cost and inaccuracy of existing methylated cytosine identification methods are solved, achieving efficient and accurate assessment of base modifications.

CN121420073APending Publication Date: 2026-01-27NANOHYBRID LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202480029104.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-02-21
Filing Date
2024-03-07
Publication Date
2026-01-27

AI Technical Summary

Technical Problem

Existing array-based methods for identifying methylated cytosine are expensive and have limited accuracy, and cannot effectively identify other base modifications. Simplified representative bisulfite sequencing (RRBS) and simplified representative methylation sequencing (RRMS) suffer from difficulties in amplification and bisulfite conversion, leading to inaccurate measurements.

Method used

By contacting the target polynucleotide with the adaptor in the presence of a ligase, followed by hybridization with a tag and binding to a solid support, the pull-down complex is separated and eluted, and finally ligated to the sequencing adaptor for sequencing, thus avoiding sequencing of the complementary adaptor-target polynucleotide and enabling targeted assessment of base modifications.

Benefits of technology

It enables cost-effective and efficient targeted assessment of base modifications in specific genomic regions, avoids measurement discrepancies caused by amplification and bisulfite conversion, and improves identification accuracy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121420073A_ABST
    Figure CN121420073A_ABST
Patent Text Reader

Abstract

Provided herein, inter alia, are methods for sequencing polynucleotides. In addition, provided herein are methods for detecting base modifications, such as methylation interpretation, in polynucleotides by sequencing only native strands. The key innovation of the method is that after hybridization, a second strand is generated, and the second strand is configured to allow the adaptor to be connected to only one end. This limits sequencing to native strands, i.e., unique strands with potential modifications.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references to related applications This application is an international application that claims priority to U.S. Provisional Application No. 63 / 450,472, filed March 7, 2023, and U.S. Provisional Application No. 63 / 556,299, filed February 21, 2024, each of which is incorporated herein by reference in its entirety and for all purposes. Background Technology

[0002] Quantifying the location and frequency of base modifications (especially methylated cytosine) in the genome is an essential tool for studying gene regulation, epigenetics, and other biological processes, as well as for clinical disease diagnosis. Current array-based methods for identifying methylated cytosine are expensive, have limited accuracy and dynamic range, and cannot identify other base modifications or determine the type of methylation present. In response, researchers in laboratories and clinics are increasingly turning to reduced representative bisulfite sequencing (RRBS) or reduced representative methylation sequencing (RRMS). However, RRBS is technically limited by the difficulty and inconsistency of enriching bisulfite-converted DNA in regions of interest. Furthermore, RRMS is generally not a practical alternative because it requires extensive sequencing of the entire genome. Therefore, there is a need for improved methods to target and evaluate modified bases at specific genomic regions in a cost-effective and accurate manner. Ideally, this technique should avoid the two main factors leading to assay discrepancies: amplification and bisulfite (or enzymatic) conversion of unmethylated cytosine. This disclosure addresses these and other problems in the art. Summary of the Invention

[0003] In one aspect, a method for detecting base modifications in a target polynucleotide is provided, the method comprising: (a) contacting the target polynucleotide with the one or more intransitive protons in the presence of a first ligase to generate an intransitive-target polynucleotide, wherein the one or more intransitive protons contain a primer binding site; (b) contacting the intransitive-target polynucleotide with the one or more tags to generate a tagged intransitive-target polynucleotide, wherein the one or more tags are complementary to one or more regions of the target polynucleotide; and (c) contacting the tagged intransitive-target polynucleotide with a solid support to promote hybridization of the one or more tags. (d) generating a pull-down complex; (e) isolating the pull-down complex; (f) optionally eluting the adaptor-target polynucleotide from the pull-down complex; (g) contacting the pull-down complex or the eluted adaptor-target polynucleotide with a first polymerase under conditions that promote the generation of a complementary adaptor-target polynucleotide, wherein the complementary adaptor-target polynucleotide contains a 3' or 5' protecting group; (g) in the presence of a second ligase, contacting the adaptor-target polynucleotide with the sequencing adaptor under conditions that promote the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex; and (h) sequencing the sequencing complex, wherein the sequencing includes sequencing the target polynucleotide sequence without sequencing the complementary adaptor-target polynucleotide, thereby detecting the base modification in the target polynucleotide.

[0004] In another aspect, a method for sequencing a target polynucleotide is provided, the method comprising: (a) contacting the target polynucleotide with the one or more intransitive protons in the presence of a first ligase to generate an intransitive-target polynucleotide, wherein the one or more intransitive protons contain a primer binding site; (b) contacting the intransitive-target polynucleotide with the one or more tags to generate a tagged intransitive-target polynucleotide, wherein the one or more tags are complementary to one or more regions of the target polynucleotide; and (c) contacting the tagged intransitive-target polynucleotide with a solid support to generate a pull-down complex. d) separating the pull-down complex; (e) optionally eluting the adaptor-target polynucleotide from the pull-down complex; (f) contacting the pull-down complex or the eluted adaptor-target polynucleotide with a first polymerase under conditions that promote the generation of complementary adaptor-target polynucleotides, wherein the complementary adaptor-target polynucleotide contains a 3' or 5' protecting group; (g) in the presence of a second ligase, contacting the adaptor-target polynucleotide with the sequencing adaptor under conditions that promote the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex; and (h) sequencing the sequencing complex, wherein the sequencing includes sequencing the target polynucleotide sequence without sequencing the complementary adaptor-target polynucleotide, thereby sequencing the target polynucleotide, wherein optionally the target polynucleotide contains one or more base modifications.

[0005] In another aspect, a method for quantifying base modifications in a target polynucleotide is provided, the method comprising: (a) contacting the target polynucleotide with the one or more intransitive protons in the presence of a first ligase to generate an intransitive-target polynucleotide, wherein the one or more intransitive protons contain a primer binding site; (b) contacting the intransitive-target polynucleotide with the one or more tags to generate a tagged intransitive-target polynucleotide, wherein the one or more tags are complementary to one or more regions of the target polynucleotide; and (c) contacting the tagged intransitive-target polynucleotide with a solid support to promote hybridization of the one or more tags. (d) generating a pull-down complex; (e) eluting the pull-down complex; (f) optionally eluting the adaptor-target polynucleotide from the pull-down complex; (g) contacting the pull-down complex or the eluted adaptor-target polynucleotide with a first polymerase under conditions that promote the generation of a complementary adaptor-target polynucleotide, wherein the complementary adaptor-target polynucleotide contains a 3' or 5' protecting group; (g) in the presence of a second ligase, contacting the adaptor-target polynucleotide with the sequencing adaptor under conditions that promote the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex; and (h) sequencing the sequencing complex, wherein the sequencing includes sequencing the target polynucleotide sequence without sequencing the complementary adaptor-target polynucleotide, thereby quantifying the base modification in the target polynucleotide.

[0006] In another aspect, a method is provided for detecting multiple base modifications in a plurality of target polynucleotides, the method comprising: (a) contacting the plurality of target polynucleotides with the one or more in the presence of a first ligase, under conditions that promote the ligation of one or more introducing agents to the plurality of target polynucleotides, to generate a plurality of introducing agent-target polynucleotides, wherein the one or more introducing agents contain primer binding sites; (b) contacting the plurality of introducing agent-target polynucleotides with the one or more introducing agents, under conditions that promote the hybridization of one or more tags to the plurality of introducing agent-target polynucleotides, to generate a plurality of tagged introducing agent-target polynucleotides, wherein the one or more tags are complementary to one or more regions of the plurality of target polynucleotides; and (c) contacting the plurality of tagged introducing agent-target polynucleotides with a solid support, under conditions that promote the hybridization of the one or more tags to a solid support, to generate a plurality of pull-downs. (d) separating the plurality of pull-down complexes; (e) optionally eluting the plurality of adaptor-target polynucleotides from the plurality of pull-down complexes; (f) contacting the plurality of pull-down complexes or the plurality of eluted adaptor-target polynucleotides with a first polymerase under conditions that promote the generation of a plurality of complementary adaptor-target polynucleotides, wherein each of the complementary adaptor-target polynucleotides contains a 3' or 5' protecting group; (g) in the presence of a second ligase, contacting the plurality of adaptor-target polynucleotides with the plurality of sequencing adaptors under conditions that promote the ligation of a plurality of sequencing adaptors to the plurality of adaptor-target polynucleotides to generate a plurality of sequencing complexes; and (h) sequencing the plurality of sequencing complexes, wherein the sequencing includes sequencing the plurality of target polynucleotide sequences without sequencing the plurality of complementary adaptor-target polynucleotides, thereby detecting a plurality of base modifications in the plurality of target polynucleotides.

[0007] In another aspect, a method for sequencing multiple target polynucleotides is provided, the method comprising: (a) contacting the multiple target polynucleotides with the one or more insulators in the presence of a first ligase, under conditions that promote the ligation of one or more insulators to the multiple target polynucleotides to generate multiple insulator-target polynucleotides, wherein the one or more insulators contain primer binding sites; (b) contacting the multiple insulator-target polynucleotides with the one or more tags in conditions that promote hybridization of one or more tags to the multiple insulator-target polynucleotides to generate multiple tagged insulator-target polynucleotides, wherein the one or more tags are complementary to one or more regions of the multiple target polynucleotides; (c) contacting the multiple tagged insulator-target polynucleotides with a solid support in conditions that promote hybridization of the one or more tags to the solid support to generate multiple pull-down complexes; and (d) separating the multiple insulator-target polynucleotides. (e) optionally eluting the plurality of adaptor-target polynucleotides from the plurality of pull-down complexes; (f) contacting the plurality of pull-down complexes or the plurality of eluted adaptor-target polynucleotides with a first polymerase under conditions that promote the generation of a plurality of complementary adaptor-target polynucleotides, wherein each of the complementary adaptor-target polynucleotides contains a 3' protecting group or a 5' protecting group; (g) in the presence of a second ligase, contacting the plurality of adaptor-target polynucleotides with the plurality of sequencing adaptors under conditions that promote the ligation of a plurality of sequencing adaptors to the plurality of adaptor-target polynucleotides to generate a plurality of sequencing complexes; and (h) sequencing the plurality of sequencing complexes, wherein the sequencing includes sequencing the plurality of target polynucleotide sequences without sequencing the plurality of complementary adaptor-target polynucleotides, thereby sequencing the plurality of target polynucleotides, wherein optionally the plurality of target polynucleotides contains one or more base modifications.

[0008] In another aspect, a method for detecting multiple base modifications in a target polynucleotide is provided, the method comprising: (a) contacting the target polynucleotide with the one or more intransitive protons in the presence of a first ligase to generate an intransitive-target polynucleotide, wherein the one or more intransitive protons contain a primer binding site; (b) contacting the intransitive-target polynucleotide with the one or more tags to generate a tagged intransitive-target polynucleotide, wherein the one or more tags are complementary to one or more regions of the target polynucleotide; and (c) contacting the tagged intransitive-target polynucleotide with a solid support to promote hybridization of the one or more tags. (d) generating a pull-down complex; (e) eluting the pull-down complex; (f) optionally eluting the adaptor-target polynucleotide from the pull-down complex; (g) contacting the pull-down complex or the eluted adaptor-target polynucleotide with a first polymerase under conditions that promote the generation of a complementary adaptor-target polynucleotide, wherein the complementary adaptor-target polynucleotide contains a 3' or 5' protecting group; (g) in the presence of a second ligase, contacting the adaptor-target polynucleotide with the sequencing adaptor under conditions that promote the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex; and (h) sequencing the sequencing complex, wherein the sequencing includes sequencing the target polynucleotide sequence without sequencing the complementary adaptor-target polynucleotide, thereby detecting the plurality of base modifications in the target polynucleotide.

[0009] In another aspect, a method for detecting base modifications in a plurality of target polynucleotides is provided, the method comprising: (a) contacting the plurality of target polynucleotides with the one or more in the presence of a first ligase, under conditions that promote the ligation of one or more introducing agents to the plurality of target polynucleotides, to generate a plurality of introducing agent-target polynucleotides, wherein the one or more introducing agents contain primer binding sites; (b) contacting the plurality of introducing agent-target polynucleotides with the one or more introducing agents, under conditions that promote the hybridization of one or more tags to the plurality of introducing agent-target polynucleotides, to generate a plurality of tagged introducing agent-target polynucleotides, wherein the one or more tags are complementary to one or more regions of the plurality of target polynucleotides; and (c) contacting the plurality of tagged introducing agent-target polynucleotides with a solid support, under conditions that promote the hybridization of the one or more tags to a solid support, to generate a plurality of pull-downs. (d) separating the plurality of pull-down complexes; (e) optionally eluting the plurality of adaptor-target polynucleotides from the plurality of pull-down complexes; (f) contacting the plurality of pull-down complexes or the plurality of eluted adaptor-target polynucleotides with a first polymerase under conditions that promote the generation of a plurality of complementary adaptor-target polynucleotides, wherein each of the complementary adaptor-target polynucleotides contains a 3' or 5' protecting group; (g) in the presence of a second ligase, contacting the plurality of adaptor-target polynucleotides with the plurality of sequencing adaptors under conditions that promote the ligation of a plurality of sequencing adaptors to the plurality of adaptor-target polynucleotides to generate a plurality of sequencing complexes; and (h) sequencing the plurality of sequencing complexes, wherein the sequencing includes sequencing the plurality of target polynucleotide sequences without sequencing the plurality of complementary adaptor-target polynucleotides, thereby detecting base modifications in the plurality of target polynucleotides. Attached Figure Description

[0010] Figure 1 shows an exemplary schematic diagram of an enrichment method for interpreting native methylation. Step 1: Connect a linker containing a primer binding site (orange) and a barcode (purple) to the input DNA. Step 2: Hybridize the input DNA with a biotinylated DNA polynucleotide complementary to the region of interest. Step 3: Use streptavidin beads to pull down and separate the desired region. Step 4: Elute the DNA from the beads. Step 5: Synthesize the complementary strand using a primer and polymerase at the 3' end of the DNA. Polymerase activity also leaves an A at the other end. Step 6: Add a sequencing linker to the end of the DNA opposite the primer site. The result is that only the native strand is sequenced.

[0011] Figures 2A and 2B show the experimental results obtained using natural methylation interpretation after enrichment. Figure 2A: Histogram of methylation frequencies at enrichment sites, showing the entire methylation range identified. Figure 2B: Correlation between microarray methylation frequencies and Nanohyb enriched regions after nanopore sequencing. The correlation is similar to the level observed between whole-genome methylation sequencing and array sequencing.

[0012] Figures 3A and 3B show the results of the analysis of methylation patterns in sperm.

[0013] Figure 4 shows the copy number variations (CNVs) detected using the method described in this paper. Detailed Implementation

[0014] After reading this specification, those skilled in the art will understand how this disclosure can be implemented in various alternative embodiments and applications. However, not all various embodiments of the invention will be described herein. It should be understood that the embodiments presented herein are presented by way of example only and not by way of limitation. Therefore, the detailed description of various alternative embodiments should not be construed as limiting the scope or breadth of the disclosure as set forth herein.

[0015] Before disclosing and describing this technology, it should be understood that the aspects described below are not limited to specific compositions, methods of preparing such compositions, or their uses, as these can certainly vary. It should also be understood that the terminology used herein is for the purpose of describing specific aspects only and is not intended to be limiting.

[0016] The detailed descriptions have been divided into different chapters solely for the convenience of the reader, and disclosures found in any chapter may be combined with disclosures in another chapter. Titles or subtitles may be used in this patent specification for the reader's convenience, but this is not intended to affect the scope of this disclosure.

[0017] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. In this specification and the following claims, numerous terms will be referenced and defined as having the following meanings: The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used herein, unless the context clearly indicates otherwise, the singular forms “a” and “the” are intended to include the plural forms as well.

[0018] "Optional" or "optionally" means that the event or situation described below may or may not occur, and the description includes examples of the event or situation occurring and examples of it not occurring.

[0019] The term "about" when used before numerical names (e.g., temperature, time, quantity, concentration, etc., including range) indicates an approximation that may vary by (+) or (-) 10%, 5%, 1%, or any subrange or subvalue in between. Preferably, when used with respect to a quantity, the term "about" means that the quantity may vary by + / - 10%.

[0020] As used herein, the term "each" when used to refer to a group of items is intended to identify an individual item within that group, but does not necessarily refer to every single item in the group. Exceptions may occur if explicitly stated or if the context clearly indicates otherwise.

[0021] The term "comprising / including" is intended to mean that the composition and method include the listed elements, but does not exclude other elements. "Substantially composed of" when used to define a composition and method means excluding any other elements that are essential to the combination for the stated use. Therefore, a composition substantially composed of the elements as defined herein does not exclude other materials or steps that do not materially affect one or more essential and novel features of the claimed invention. "Composed of" means excluding elements and substantial method steps containing other ingredients in greater than trace amounts. Embodiments defined by each of these transitional terms are within the scope of this disclosure.

[0022] As used herein, the terms “nucleic acid,” “nucleic acid molecule,” “nucleic acid oligomer,” “oligonucleotide,” “nucleic acid sequence,” “nucleic acid fragment,” and “polynucleotide” are used interchangeably and are intended to include, but are not limited to, polymeric forms (deoxyribonucleotides or ribonucleotides) of nucleotides covalently linked together, or their analogs, derivatives, or modifications, that may have various lengths. Different polynucleotides may have different three-dimensional structures and may perform a variety of known or unknown functions. Non-limiting examples of polynucleotides include genes, gene fragments, exons, introns, intergenic DNA (including, but not limited to, heterochromatin DNA), messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched-chain polynucleotides, plasmids, vectors, sequence-isolated DNA, sequence-isolated RNA, nucleic acid probes, and primers. Polynucleotides used in the methods of this disclosure may include natural nucleic acid sequences and their variants, artificial nucleic acid sequences, or combinations of such sequences.

[0023] Polynucleotides are typically composed of a specific sequence of four nucleotide bases: adenine (A); cytosine (C); guanine (G); and thymine (T) (when the polynucleotide is RNA, thymine (T) is replaced by uracil (U)). Therefore, the term "polynucleotide sequence" is a letter representation of a polynucleotide molecule; alternatively, the term can also be applied to the polynucleotide molecule itself. This letter representation can be entered into a database on a computer with a central processing unit and used for bioinformatics applications such as functional genomics and homology searches. Polynucleotides may optionally include one or more non-standard nucleotides, nucleotide analogs, and / or modified nucleotides.

[0024] “Nucleic acid” refers to nucleotides (e.g., deoxyribonucleotides or ribonucleotides) in single-stranded, double-stranded, or multi-stranded forms, their polymers, or complementary sequences thereof; or nucleosides (e.g., deoxyribonucleosides or ribonucleosides). In embodiments, “nucleic acid” does not include nucleosides. The terms “polynucleotide,” “oligonucleotide,” “oligonucleotide,” etc., generally and conventionally refer to a straight-chain sequence of nucleotides. The term “nucleoside” generally and conventionally refers to a glycosamine comprising a nucleobase and a pentose sugar (ribose or deoxyribose). Non-limiting examples of nucleosides include cytidine, uridine, adenosine, guanosine, thymidine, and inosine. The term “nucleotide” generally and conventionally refers to a single unit of a polynucleotide, i.e., a monomer. Nucleotides can be ribonucleotides, deoxyribonucleotides, or modified forms thereof. Examples of polynucleotides considered herein include single-stranded DNA and double-stranded DNA, single-stranded RNA and double-stranded RNA, and hybrid molecules having mixtures of single-stranded and double-stranded DNA and RNA. Examples of nucleic acids (e.g., polynucleotides) considered herein include any type of RNA (e.g., mRNA, siRNA, miRNA, and guide RNA) and any type of DNA, genomic DNA, plasmid DNA, and small circular DNA, and any fragments thereof. In the context of polynucleotides, the term "double-stranded" refers to a double strand in its usual and conventional sense. Nucleic acids can be straight-chain or branched. For example, a nucleic acid can be a straight chain of nucleotides, or it can be branched, for example, such that the nucleic acid contains one or more arms or branches of a nucleotide. Optionally, branched nucleic acids are repeating branches that form higher-order structures, such as dendritic polymers, etc.

[0025] According to this disclosure, the term "nucleotide" specifically refers to ribonucleotides, 2'-deoxyribonucleotides, or 2',3'-dideoxyribonucleotides.

[0026] The term "nucleobase" refers to a natural or non-natural purine or pyrimidine base. Nucleobases include adenine, cytosine, guanine, thymine, uracil, hypoxanthine, xanthine, 7-deadenine and 7-deadenine, and inosine.

[0027] As used in this article, the phrase “dNTP” refers to 2'-deoxynucleotide triphosphate, where the nucleotide contains either a natural or non-natural nucleobase.

[0028] As used herein, when the term "double-stranded" is used with a polynucleotide, it means that some or all of the nucleotides between the complementary strands of the polynucleotide are bonded together by hydrogen bonds to form a partial or complete double helix. At least 10%, 25%, 50%, 60%, 70%, 80%, 90%, or 95% of the nucleotides in a partially double-stranded polynucleotide may be bonded to the complementary nucleotide by hydrogen bonds.

[0029] A single-stranded polynucleotide is a polynucleotide that forms few or no hydrogen bonds with another polynucleotide, and therefore does not form a double helix or is unstable under given hybridization conditions.

[0030] "Polymerase" is generally an enzyme that catalyzes the reaction between 3'-OH and 5'-triphosphate in nucleotides, oligomers and their analogues to form nucleic acid polymers. Polymerases include, but are not limited to, DNA-dependent DNA polymerase, RNA-dependent DNA polymerase, template-independent DNA polymerase, T7 DNA polymerase, T3 DNA polymerase, T4 DNA polymerase, DNA polymerase 1, Klenow fragment, Thermophilus aquaticus DNA polymerase, Tth DNA polymerase, Phusion DNA polymerase, SuperFi DNA polymerase, Vent DNA polymerase, Deep Vent DNA polymerase, Bst DNA polymerase large fragment, Stoeffel fragment, 9° N DNA polymerase, Pfu DNA polymerase, Tfl DNA polymerase, Phi29 polymerase, Tli DNA polymerase, eukaryotic DNA polymerase β, telomerase, KOD HiFi, KOD1 DNA polymerase, Q-β replicase, terminal transferase (TdT), AMV reverse transcriptase, M-MLV reverse transcriptase, Phi6 reverse transcriptase, HIV-1 reverse transcriptase, and Thermo sequencing enzyme (Thermo Fisher Scientific). These polymerases include wild-type, mutant isotypes, chimeric forms, and genetically engineered variants, such as exopolymerases and other mutants, for example, mutants that tolerate modified nucleotides and incorporate them into the nucleic acid chain.

[0031] As used herein, the term "base modification" refers to a nucleotide that is modified by the addition of a chemical group or substituted by a non-natural nucleotide or non-natural nucleoside. In embodiments, base modification includes methylation. In embodiments, base modification includes 5-methylcytosine (5mC), N-6-methyladenine (6mA), 7-methylguanine (m7G), or 2'-O-methylation (2'-O-methyl). In embodiments, base modification includes oxidation of the methylated nucleotide. In embodiments, base modification includes 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), 5-carboxycytosine (5caC), 5-hydroxymethyluracil (5hmU), 5-formyluracil (5hmU), or β-D-glucosyl-hydroxymethyluracil (base J). In embodiments, base modification includes bromodeoxyuridine (BrdU).

[0032] As used herein, the term "methylation" refers to the process of adding a methyl group to a nucleotide. In embodiments, methylation includes adding a methyl group to adenine, cytosine, or guanine. In embodiments, methylation includes 2'-O-methylation (2'-O-methyl).

[0033] As used herein, the term "non-natural nucleotide" refers to nucleotide analogs, synthetic nucleotides, and nucleotide mimics that do not exist in nature. In embodiments, non-natural nucleotides may replace naturally occurring nucleotides present in polynucleotides.

[0034] As used herein, the term "non-natural nucleoside" refers to nucleoside analogs, synthetic nucleosides, and nucleoside simulants that do not exist in nature. In embodiments, a non-natural nucleoside may replace a natural nucleoside present in a polynucleotide. In embodiments, a non-natural nucleoside may replace a natural nucleoside present in a polynucleotide. In embodiments, the non-natural nucleoside is bromodeoxyuridine (BrdU).

[0035] As used herein, the term "target polynucleotide" refers to a polynucleotide selected for sequencing. For example, but not limited to, a target polynucleotide can be a polynucleotide having or expected to have base modifications. In embodiments, a target polynucleotide can be a polynucleotide having or expected to have base modifications in a given cell type. In embodiments, a target polynucleotide can be a genomic polynucleotide. In embodiments, a target polynucleotide can be genomic DNA. In embodiments, a target polynucleotide can be a portion of the cell's genome. In embodiments, a target polynucleotide can be a fragment of the cell's genome. In embodiments, a target polynucleotide can be DNA from a specific cell type. In embodiments, a target polynucleotide can be used to identify cell types. In embodiments, a target polynucleotide can be from any compartment within the cell. In embodiments, a target polynucleotide can be a nuclear polynucleotide. In embodiments, a target polynucleotide can be nuclear DNA. In embodiments, a target polynucleotide can be a mitochondrial polynucleotide. In embodiments, a target polynucleotide can be mitochondrial DNA (mDNA). In embodiments, a target polynucleotide can be a portion of the cell's mitochondrial DNA. In embodiments, a target polynucleotide can be a fragment of mitochondrial DNA. In embodiments, a target polynucleotide can be a DNA fragment. In embodiments, a target polynucleotide can be chromosomal DNA or a fragment thereof. In embodiments, a target polynucleotide can be extracellular. In some embodiments, the target polynucleotide can be cell-free DNA (cfDNA). In some embodiments, the target polynucleotide can be contained in a biological sample. In some embodiments, the target polynucleotide can be isolated from a biological sample. In some embodiments, the target polynucleotide can be DNA from an animal. In some embodiments, the target polynucleotide can be DNA from a vertebrate. In some embodiments, the target polynucleotide can be DNA from a mammal. In some embodiments, the target polynucleotide can be DNA from a human. In some embodiments, the target polynucleotide can be DNA from a rodent. In some embodiments, the target polynucleotide can be DNA from a mouse. In some embodiments, the target polynucleotide can be DNA from a rat. In some embodiments, the target polynucleotide can be DNA from an invertebrate. In some embodiments, the target polynucleotide can be DNA from a plant. In some embodiments, the target polynucleotide can be DNA from a pathogen. In some embodiments, the target polynucleotide can be DNA from a virus. In some embodiments, the target polynucleotide can be DNA from bacteria. In some embodiments, the target polynucleotide can be DNA from a parasite. In some embodiments, the target polynucleotide can be DNA from an archaea.

[0036] As used herein, the term "adaptor" generally refers to any oligonucleotide that can be added to (e.g., linked) to a nucleic acid molecule to produce a nucleic acid product that can be sequenced on a sequencing platform. In some embodiments, the adaptor comprises two complementary oligonucleotides forming a double-stranded structure. In embodiments, the adaptor is an oligonucleotide that can be linked to the end of a target polynucleotide.

[0037] As used herein, the term "link" refers to the process of connecting two biomolecules (e.g., oligonucleotides, polynucleotides) by forming a chemical bond between their ends. In embodiments, the chemical bond is a non-covalent chemical bond. In embodiments, the linking is catalyzed by a ligase.

[0038] As used in this article, the term "ligase" refers to an enzyme that catalyzes the linking of two biomolecules (e.g., oligonucleotides, polynucleotides) by forming new chemical bonds.

[0039] As used herein, the term "adaptor-target polynucleotide" refers to a target polynucleotide to which one or more adaptors are attached to one (or both) end.

[0040] As used in this article, the term "primer binding site" is the nucleotide sequence of a polynucleotide that serves as the initiation site for primer binding and polynucleotide replication.

[0041] As used herein, the term "complementary adaptor-target polynucleotide" refers to a polynucleotide that is complementary to and hybridizes with the adaptor-target polynucleotide. In some embodiments, the complementary adaptor-target polynucleotide includes a 3' protecting group. In some embodiments, the complementary adaptor-target polynucleotide includes a 5' protecting group. In some embodiments, the complementary adaptor-target polynucleotide is wholly or substantially complementary to the adaptor-target polynucleotide. In some embodiments, the complementary adaptor-target polynucleotide is complementary to a portion of the adaptor-target polynucleotide.

[0042] As used herein, the term "3' protecting group" refers to the portion at the end of a polynucleotide that prevents sequencing of the polynucleotide. In embodiments, the 3' protecting group prevents sequencing of the complementary adaptor-target polynucleotide. In embodiments, the 3' protecting group prevents the linkage of the sequencing adaptor to the complementary adaptor-target polynucleotide. In embodiments, the 3' protecting group includes a nucleotide overhang or a 3' phosphate. In embodiments, the 3' protecting group includes a nucleotide overhang. In embodiments, the 3' protecting group includes a 3' phosphate.

[0043] As used herein, the term "5' protecting group" refers to the portion at the 5' end of a polynucleotide that prevents sequencing of the polynucleotide. In embodiments, the 5' protecting group prevents sequencing of the complementary adaptor-target polynucleotide. In embodiments, the 5' protecting group prevents the linkage of the sequencing adaptor to the complementary adaptor-target polynucleotide. In embodiments, the 5' protecting group comprises an aldehyde, amine, or thiol. In embodiments, the 5' protecting group comprises an aldehyde. In embodiments, the 5' protecting group comprises an amine. In embodiments, the 5' protecting group comprises a thiol. In embodiments, the 5' protecting group comprises a 5' aldehyde. In embodiments, the 5' protecting group comprises a 5' amine. In embodiments, the 5' protecting group comprises a 5' thiol.

[0044] As used in this article, the term "nucleotide overhang" refers to the sequence of unpaired nucleotides at the end of a polynucleotide.

[0045] As used herein, the terms “complementary” or “substantially complementary” refer to hybridization, base pairing, or double-strand formation between nucleotides or nucleic acids. For example, complementarity exists between the two strands of a double-stranded DNA molecule when the sequence of a nucleotide (e.g., RNA or DNA) or a nucleotide is capable of base pairing with the corresponding homologous nucleotide or sequence of homologous nucleotides, or between an oligonucleotide primer and a primer binding site on a single-stranded nucleic acid. As described herein and known in the art, the complementary (matching) nucleotide of adenosine (A) is thymidine (T), and the complementary (matching) nucleotide of guanosine (G) is cytosine (C). Therefore, a complementary sequence may include a sequence of nucleotides that base pair with the corresponding complementary nucleotide of a second nucleic acid sequence. The nucleotides of the complementary sequence may partially or completely match the nucleotides of the second nucleic acid sequence. When the nucleotides of the complementary sequence completely match every nucleotide of the second nucleic acid sequence, the complementary sequence forms a base pair with every nucleotide of the second nucleic acid sequence. When the nucleotides of the complementary sequence partially match the nucleotides of the second nucleic acid sequence, only some of the nucleotides of the complementary sequence form a base pair with the nucleotides of the second nucleic acid sequence. Examples of complementary sequences include coding and non-coding sequences, where the non-coding sequence contains nucleotides complementary to the coding sequence, thus forming a complementary sequence to the coding sequence. Another example of complementary sequences is a sense sequence and an antisense sequence, where the sense sequence contains nucleotides complementary to the antisense sequence, thus forming a complementary sequence to the antisense sequence. A “double strand” refers to at least two oligonucleotides and / or polynucleotides that are fully or partially complementary, with Watson-Crick type base pairing occurring between all or most of their nucleotides, forming a stable complex. In embodiments, the first and second template polynucleotides of the overlapping cluster are substantially non-complementary (e.g., at least 50%, 75%, 90%, or more non-complementary to each other).

[0046] As described herein, sequence complementarity can be partial, where only some nucleic acids match according to base pairing, or complete, where all nucleic acids match according to base pairing. Thus, two sequences complementary to each other can have a specified percentage of complementary nucleotides (e.g., about 60% within a specified region, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher complementarity). In embodiments, two sequences are complementary when they are completely complementary, having 100% complementarity. In embodiments, the sequences in a pair of complementary sequences form a portion of a single polynucleotide or a portion of a separate polynucleotide having non-base-paired nucleotides (e.g., hairpin or loop structures, with or without overhangs). In embodiments, one or both sequences in a pair of complementary sequences form a portion of a longer polynucleotide, which may or may not contain additional complementary regions.

[0047] As used herein, the term "contact" is used in its simple, general sense and refers to a process that allows at least two different substances (e.g., chemical compounds including biomolecules or cells) to come close enough to react, interact, or physically touch. However, the resulting reaction product can be generated directly from the reaction between the added reagents or from intermediates from one or more of the added reagents that can be produced in the reaction mixture. The term "contact" can include allowing two substances to react, interact, or physically touch, wherein the two substances can be compounds, nucleic acids, proteins, or enzymes (e.g., DNA polymerase).

[0048] As used herein, the term "barcode" refers to a known nucleic acid sequence that allows identification of certain characteristics of a nucleic acid associated with the barcode. In some embodiments, the nucleic acid to be identified is characterized by the sample or source from which it is derived. By way of example only, some embodiments described herein depict the addition of multiple barcodes (e.g., 2, 3, 4, 5, 6, or more barcodes) to a nucleic acid of interest in a single cell present in a cell population. The unique combination of barcodes added to the nucleic acid of each individual cell can advantageously identify the cell from which the tagged nucleic acid of interest is derived. In some embodiments, the length of the barcode is at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more nucleotides. In some embodiments, the length of the barcode is less than 10, 9, 8, 7, 6, 5, or 4 nucleotides. In some embodiments, the length of the barcode associated with some nucleic acids differs from the length of the barcode associated with other nucleic acids. Generally, a barcode contains sufficient length to identify the sample based on the barcode associated with the sample, and contains sufficient distinct sequences to identify the sample based on the barcode associated with the sample. In some embodiments, mutations, insertions, or deletions of one or more nucleotides in the barcode sequence, such as mutations, insertions, or deletions, can accurately identify the barcode and its associated sample origin. In some embodiments, each barcode in a plurality of barcodes differs from each of the other barcodes in a plurality of barcodes at two or more nucleotide positions, such as at 2, 3, 4, 5, 6, 7, 8, 9, 10, or more positions. In some embodiments, one or more adaptors contain at least one barcode sequence from a plurality of barcode sequences. In some embodiments, the method further includes identifying the sample or origin from which the target nucleic acid is derived based on the barcode sequence to which the target nucleic acid is attached. In some embodiments, the method further includes identifying the target nucleic acid based on the barcode sequence to which the target nucleic acid is attached. Some embodiments of the method further include identifying the origin or sample of the target nucleotide sequence by determining the barcode nucleotide sequence. Some implementations of this method also include molecular counting applications (e.g., digital barcode enumeration and / or box merging) to determine the expression level or copy number state of the desired target. Generally, the barcode may contain a nucleic acid sequence that serves as an identifier of the sample from which the target polynucleotide is derived when linked to the target nucleic acid.

[0049] As used herein, the term "primer" or "extension primer" refers to a naturally occurring or synthetically produced oligonucleotide that, when placed under appropriate conditions, such as in the presence of a nucleotide triphosphate and a polymerase (e.g., a thermostable polymerase) in a suitable buffer ("buffer" includes appropriate pH, ionic strength, cofactors, etc.) and at a suitable temperature, can serve as the starting point for nucleic acid synthesis. In some embodiments, primers may be single-stranded to achieve maximum amplification efficiency, but they may also be double-stranded. If the primer is double-stranded, it is first treated to separate its strands before being used to prepare the extension product. In some embodiments, the primer is an oligodeoxyribonucleotide. The primer must be long enough to initiate the synthesis of the extension product. The exact length of the primer will depend on a variety of factors, including temperature, primer source, polymerase (e.g., whether it is thermostable), and the method used.

[0050] Nucleic acids can contain nonspecific sequences. As used herein, the term "nonspecific sequence" refers to a nucleic acid sequence containing a set of residues that are designed not to be complementary to any other nucleic acid sequence or to be only partially complementary to any other nucleic acid sequence. As an example, a nonspecific nucleic acid sequence is a sequence of nucleic acid residues that does not act as an inhibitory nucleic acid when in contact with a cell or organism.

[0051] As used herein, the term "complementary sequence" refers to a sequence of nucleotides (e.g., RNA or DNA) or nucleotides capable of base pairing with a sequence of complementary nucleotides or nucleotides. As described herein and known in the art, the complementary (matching) nucleotide of adenosine is thymidine, and the complementary (matching) nucleotide of guanosine is cytosine. Therefore, a complementary sequence can comprise a sequence of nucleotides that base pair with the corresponding complementary nucleotide of a second nucleic acid sequence. The nucleotides of the complementary sequence may partially or completely match the nucleotides of the second nucleic acid sequence. When the nucleotides of the complementary sequence completely match every nucleotide of the second nucleic acid sequence, the complementary sequence forms a base pair with every nucleotide of the second nucleic acid sequence. When the nucleotides of the complementary sequence partially match the nucleotides of the second nucleic acid sequence, only some of the nucleotides of the complementary sequence form a base pair with the nucleotides of the second nucleic acid sequence. Examples of complementary sequences include coding and non-coding sequences, wherein the non-coding sequence contains nucleotides complementary to the coding sequence, thus forming a complementary sequence of the coding sequence. Another example of complementary sequences is a sense sequence and an antisense sequence, wherein the sense sequence contains nucleotides complementary to the antisense sequence, thus forming a complementary sequence of the antisense sequence.

[0052] As described herein, sequence complementarity can be partial, where only some nucleic acids match according to base pairing, or complete, where all nucleic acids match according to base pairing. Therefore, two complementary sequences can have a specified percentage of identical nucleotides (i.e., approximately 60% identity within a specified region, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher identity).

[0053] As used herein, the terms “library,” “RNA library,” “DNA library,” or “library of DNA molecules” are used according to their common meaning and refer to a collection or group of nucleic acid fragments of similar size having known adaptor sequences (e.g., known adaptors linked to the 5' and 3' ends of each fragment). In embodiments, a library contains multiple nucleic acid fragments that contain one or more adaptor sequences. In embodiments, a library includes a circular nucleic acid template. Libraries are typically prepared from input RNA, DNA, or cDNA and are processed through fragmentation, size selection, end repair, adaptor ligation, amplification, and purification. Alternative amplification-free (i.e., PCR-free) methods for preparing libraries of molecules include splicing of the input polynucleotide, size selection, and adaptor ligation. Libraries may correspond to a single sample or a single source. Multiple libraries (each with its own unique adaptor sequences) can be combined and sequenced in the same sequencing run using the methods described herein.

[0054] As used herein, the terms “extension” or “stretching” are used in their ordinary sense and refer to the synthesis by polymerase of a new polynucleotide chain (e.g., “extended chain”) complementary to the template strand by adding a free nucleotide (e.g., dNTP) complementary to the template in the 5' to 3' direction from the reaction mixture, including condensing the 5'-phosphate group of the dNTP with a 3'-hydroxyl group at the end of the nascent (extended) DNA strand.

[0055] As used herein, the terms “sequencing,” “sequencing determination,” “determining nucleotide sequence,” etc., encompass determining partial or complete sequence information, including the identification, sequencing, or localization of nucleotides constituting the sequenced polynucleotide, and include the physical processes that generate such sequence information. That is, the term includes sequence comparison, consensus sequence determination, contig assembly, fingerprinting, and similar-level information about the target polynucleotide, as well as the definitive identification and sequencing of nucleotides within the target polynucleotide. The term also includes the identification, sequencing, and location of one, two, or three of the four nucleotides within the target polynucleotide. In some embodiments, the sequencing process described herein includes contacting a template and annealing primers with a suitable polymerase under conditions suitable for polymerase extension and / or sequencing.

[0056] As used herein, the term "sequencing read" is used in its simple and common sense and refers to the inferred sequence (or probability of nucleotide bases) corresponding to all or part of a single polynucleotide fragment. Sequencing reads may include 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more nucleotide bases.

[0057] The term "gene" refers to a segment of DNA involved in the production of proteins; it includes the regions preceding and following the coding regions (leader and tail sequences) and the intermediate sequences (introns) between the individual coding regions (exons). Leader sequences, tail sequences, and introns contain regulatory elements essential for gene transcription and translation. Furthermore, a "protein gene product" is a protein expressed by a specific gene.

[0058] As used herein, the term “hybridization” or “specific hybridization” refers to the process of annealing two complementary nucleic acid strands to each other under appropriately stringent conditions. Hybridization is typically and preferably performed using oligonucleotides. The terms “annealing” and “hybridization” are used interchangeably, referring to the formation of a stable double helix. The tendency of nucleic acids to hybridize depends on the temperature and ionic strength of their environment, the length of the nucleic acids, and the degree of complementarity. The effects of these parameters on hybridization are described, for example, in Sambrook J., Fritsch E. F., Maniatis T., *Molecular cloning: a laboratory manual*, Cold Spring Harbor Laboratory Press, New York (1989). Those skilled in the art will understand how to estimate and adjust the stringency of hybridization conditions so that sequences with at least the desired level of complementarity hybridize stably, while sequences with lower complementarity do not hybridize. As used herein, hybridization of primers, or hybridization of DNA extension products, can be achieved by forming phosphodiester bonds with available nucleotides or nucleotide analogs capable of forming phosphodiester bonds with them.

[0059] For the specific proteins described herein, the term "protein" includes any of the naturally occurring forms, variants, or homologs of proteins that maintain protein transcription factor activity (e.g., within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% activity compared to the native protein). In some embodiments, the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., 50, 100, 150, or 200 consecutive amino acid segments) compared to the naturally occurring form. In other embodiments, the protein is identified by its NCBI sequence reference. In other embodiments, the protein is identified by its NCBI sequence reference, homologs, or functional fragments thereof.

[0060] As used herein, when the term "library" refers to nucleic acids, it means a collection of nucleic acids with different chemical compositions (e.g., different sequences, different lengths, etc.). Typically, the nucleic acids in a library will be different substances that share common characteristics or properties of a genus or class, but differ in other respects. For example, a library may contain nucleic acid substances with different nucleotide sequences but similar sugar-phosphate backbones. Libraries can be generated using techniques known in the art. The nucleic acids exemplified herein can include nucleic acids obtained from any source, including, for example, nucleic acids obtained from the digestion of a genome (e.g., the human genome) or a mixture of genomes. In another instance, nucleic acids can be nucleic acids obtained from metagenomic studies of a specific environment or ecosystem. The term also includes artificially generated nucleic acid libraries, such as DNA libraries.

[0061] The terms “click chemistry” and “click reaction” are used interchangeably herein and are intended to be consistent with their use in the art. Generally, click chemistry reactions are rapid (e.g., fast-completing), simple, easily purified, and region-specific. Click chemistry includes reactions such as, but not limited to, copper-catalyzed azide-alkyne cycloaddition (CuAAC); ring-strain-promoted azide-alkyne cycloaddition (SPAAC) (also known as copper-free click chemistry); ring-strain-promoted alkyne-nitroketone cycloaddition (SPANC); alkyne hydrothiolation; and olefin hydrothiolation. Click chemistry using copper as a catalyst typically involves an unstable Cu(I) stabilizing ligand. Without being bound by any particular theory, the ligand can stabilize or protect the Cu(I) ion from oxidation from reactive Cu(I) to Cu(II) and can also act as a proton acceptor, reducing or eliminating the need for a base in the reaction. In some embodiments, click chemistry between polynucleotides can be facilitated by using portions that bring the two reaction partners close enough for the reaction to occur.

[0062] As used herein, unless otherwise specified, the term "azide" or "azide group" refers to N3, or —N═N+═N-, or ─N-─N+ºN.

[0063] As used herein, a “tag” is a chemical or biochemical part of a nucleic acid. “Tags” include, for example, fluorescent agents, chemiluminescent agents, affinity agents, blocking groups, chromogenic agents, quenchers, radioactive nucleotides, enzymes, substrates, cofactors, inhibitors, nanoparticles, magnetic particles, and other groups known in the art. Tags are capable of generating measurable signals and can be covalently or non-covalently linked to oligonucleotides or nucleotides. In some instances, an oligonucleotide or a portion of an oligonucleotide tethered as disclosed herein can serve as a tag.

[0064] As used herein, the term “tagged adaptor-target polynucleotide” refers to having one or more tagged adaptor-target polynucleotides bound to it.

[0065] As used herein, the term "tag" refers to a biomolecule capable of binding to an adaptor-target polynucleotide. In embodiments, the tag comprises a polynucleotide sequence complementary to a region of the target polynucleotide. In embodiments, the tag is capable of binding to the complementary region of the target polynucleotide. In embodiments, the tag comprises half of a homology binding pair.

[0066] As used herein, the term "solid support" refers to an insoluble, chemically inert object having a solid surface. Examples of solid supports provided herein include, but are not limited to, beads, pillars, chips, pores, arrays, microfluidic channels, resins, particles, micron-sized particles, or nanoparticles. In embodiments, the surface of the solid support may be smooth, porous, or granular. In embodiments, the solid support comprises half of a homologous pair. In embodiments, the surface of the solid support comprises half of a homologous pair.

[0067] As used herein, the term "homologous binding pair" refers to a pair of biomolecules that are non-covalently bound to each other. In embodiments, a homologous binding pair comprises a capture portion and a binding portion. In some embodiments, a solid support comprises the capture portion. In some embodiments, a tag comprises the binding portion. In embodiments, the non-covalent binding of homologous pairs forms a homologous capture complex. In some embodiments, the non-covalent binding of homologous pairs forms a pull-down complex. In embodiments, homologous pairs include binding pairs of streptavidin and biotin, maltose and maltose-binding protein, glutathione and glutathione S-transferase, chitin and chitin-binding protein, aptamers and their antigens, SpyCatcher and SpyTag, or antibodies and their antigens. In embodiments, homologous pairs include binding pairs of streptavidin and biotin. In embodiments, homologous pairs include binding pairs of maltose and maltose-binding protein. In embodiments, homologous pairs include binding pairs of glutathione and glutathione S-transferase. In embodiments, homologous pairs include binding pairs of chitin and chitin-binding protein. In some embodiments, homology pairs include binding pairs between aptamers and their antigens. In some embodiments, homology pairs include binding pairs between SpyCatcher and SpyTag. In some embodiments, homology pairs include binding pairs between antibodies and their antigens.

[0068] As used herein, the term "pull-down complex" refers to a complex formed when the binding portion hybridizes with its corresponding capture portion, thereby binding the tagged adaptor-target polynucleotide to a solid support. In embodiments, the pull-down complex comprises a tagged adaptor-target polynucleotide and a solid support.

[0069] As used herein, the term "sequencing adaptor" refers to a synthetic oligonucleotide or synthetic polynucleotide that is side-joined to or flanks any side of a polynucleotide sequence to be sequenced. In some embodiments, the sequencing adaptor includes a flow cell binding sequence. In some embodiments, the sequencing adaptor includes a sequencer primer binding site. In some embodiments, the sequencing adaptor includes an index region or barcode region. In some embodiments, the sequencing adaptor includes a motor protein binding site.

[0070] As used herein, the term "motor protein binding site" refers to an oligonucleotide sequence that allows a motor protein to bind. In embodiments, the motor protein is a polypeptide that unwinds a double-stranded polynucleotide to allow sequencing of a single-stranded polynucleotide. In embodiments, the motor protein includes helicase activity.

[0071] As used herein, the term "flow cell binding sequence" refers to an oligonucleotide sequence complementary to an oligonucleotide linked to a sequencing flow cell. In an implementation, the flow cell binding sequence binds the polynucleotide sequence of interest to the flow cell.

[0072] As used herein, the term "sequencing primer binding site" refers to an oligonucleotide sequence that allows sequencing primers to bind. In an embodiment, the sequencing primer is a synthetic oligonucleotide that recruits and binds to a polymerase that extends oligonucleotide synthesis.

[0073] As used herein, the terms "index region" or "barcode region" refer to a region of a sequencing adaptor that allows identification of a single sequencing adaptor. In an implementation, one or more sequencing adaptors contain one or more index regions that allow multiple runs.

[0074] As used herein, the term "sequencing complex" refers to a complex formed by linking one or more sequencing adaptors to an adaptor-target polynucleotide. In an embodiment, the sequencing complex comprises one or more sequencing adaptors and an adaptor-target polynucleotide.

[0075] As used herein, the term "sequencing" refers to the process of determining the sequence of a biopolymer. In this embodiment, the biopolymer is a polynucleotide. In this embodiment, sequencing does not include bisulfite sequencing. In this embodiment, sequencing does not include whole-genome sequencing.

[0076] As used herein, the term "bisulfite sequencing" refers to a sequencing method used to determine the methylation patterns of polynucleotides. In embodiments, bisulfite sequencing includes bisulfite conversion. In embodiments, bisulfite conversion includes treating the polynucleotide with bisulfite prior to sequencing. In embodiments, bisulfite treatment introduces specific changes in the sequence of the polynucleotide. In embodiments, bisulfite treatment converts cytosine residues to uracil residues. In embodiments, bisulfite treatment does not convert 5-methylcytosine residues to uracil residues. In embodiments, bisulfite sequencing includes reduced representative bisulfite sequencing (RRBS).

[0077] As used herein, the term "Reduced Representative Bisulfite Sequencing" or "RRBS" refers to a sequencing technique that analyzes whole-genome methylation patterns at the single nucleotide level. In this implementation, RRBS involves restriction enzyme enrichment and bisulfite sequencing of genomic regions with high CpG content. In this implementation, RRBS does not target any promoter regions.

[0078] As used herein, the terms "reduced methylation sequencing" or "RRMS" refer to sequencing technologies that can analyze whole-genome methylation patterns without bisulfite conversion. In implementations, RRMS includes adaptive sampling to enrich regions of interest. In implementations, adaptive sampling removes off-target regions during sequencing.

[0079] As used in this article, the term “whole genome sequencing” or “WGS” refers to sequencing technology used to determine all or almost all of the nucleotide sequences of an organism’s genome.

[0080] As used herein, the term “cell-free DNA” or “cfDNA” refers to a freely circulating (e.g., not contained within cells) DNA fragment present in a biological sample.

[0081] "Biological sample" or "sample" refers to a substance obtained or derived from a subject or patient. Biological samples include tissue sections (such as biopsy and autopsy samples) and frozen sections collected for histological purposes. Such samples include bodily fluids (such as blood and blood fractions or products (e.g., serum, plasma, platelets, erythrocytes, etc.)), sputum, tissues, cultured cells (e.g., primary cultures, explants, and transformed cells), feces, urine, semen, synovial fluid, joint tissue, synovial tissue, synovial cells, fibroblast-like synovial cells, macrophage-like synovial cells, immune cells, hematopoietic cells, fibroblasts, macrophages, T cells, etc. Biological samples are typically obtained from eukaryotes, such as mammals, such as primates (e.g., chimpanzees or humans); cows; horses; goats; pigs; dogs; cats; rodents, such as guinea pigs, rats, mice; rabbits; or birds; reptiles; or fish. In some embodiments, biological samples are obtained from vertebrates. In others, biological samples are obtained from invertebrates. In one implementation, the biological sample is obtained from bacteria. In another implementation, the biological sample is obtained from a virus. In yet another implementation, the biological sample is obtained from a plant. In yet another implementation, the biological sample is obtained from an archaea.

[0082] As used herein, the term "barcode" refers to a known nucleic acid sequence that allows identification of certain characteristics of a polynucleotide associated with the barcode. In some embodiments, the polynucleotide to be identified is characterized by the sample or source from which the polynucleotide is derived. In some embodiments, the barcode is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more nucleotides long. In some embodiments, the barcode is shorter than 10, 9, 8, 7, 6, 5, or 4 nucleotides long. In some embodiments, the length of the barcode associated with some polynucleotides differs from the length of the barcode associated with other polynucleotides. Generally, the barcode contains a length sufficient to identify the sample based on the barcode associated with the sample, and contains a distinct sequence sufficient to identify the sample based on the barcode associated with the sample. In some embodiments, each barcode in the plurality of barcodes differs from each of the other barcodes in two or more nucleotide positions, such as 2, 3, 4, 5, 6, 7, 8, 9, 10 or more positions. In some embodiments, one or more adaptors contain at least one barcode sequence from the plurality of barcode sequences. In some embodiments, the method further includes identifying the polynucleotide based on the barcode sequence to which the polynucleotide is attached. Generally, the barcode may contain an oligonucleotide sequence that, when attached to a polynucleotide, serves as an identifier of the sample from which the polynucleotide is derived.

[0083] method This document provides methods for sequencing target polynucleotides. In some embodiments, the target polynucleotides are enriched without amplification. In some embodiments, sequencing includes detecting or identifying base modifications in the target polynucleotides.

[0084] In some embodiments, the method includes a first step: linking an adaptor to a target polynucleotide. In some embodiments, the first step includes linking one or more adaptors to a target polynucleotide to form an adaptor-target polynucleotide. In some embodiments, one or more adaptors contain a primer binding site.

[0085] In some embodiments, the method includes a second step: hybridizing the tag with a target polynucleotide. In some embodiments, the second step includes hybridizing one or more tags with a target polynucleotide to form a tagged adaptor-target polynucleotide. In some embodiments, one or more tags comprise a polynucleotide sequence complementary to the target polynucleotide. In some embodiments, one or more tags comprise half of a homology pair. In some embodiments, one or more tags comprise a binding moiety.

[0086] In some embodiments, the method includes a third step: forming a pull-down complex. In some embodiments, the formation of the pull-down complex includes the binding of homologous pairs. In some embodiments, the formation of the pull-down complex includes the binding of a binding portion to a capture portion. In some embodiments, the pull-down complex comprises a tagged adaptor-target polynucleotide bound to a solid support. In some embodiments, the solid support comprises half of a homologous pair. In some embodiments, the solid support comprises a capture portion.

[0087] In some embodiments, the method includes a fourth step: pulling down the target polynucleotide. In some embodiments, the fourth step includes separating the pull-down complex. In some embodiments, the separation of the pull-down complex enriches the target polynucleotide. In some embodiments, the separation of the pull-down complex may include exposing the pull-down complex to a magnet. In some embodiments, the separation of the pull-down complex may include exposing the pull-down complex to a magnet for about 1 minute. In some embodiments, the separation of the pull-down complex may include exposing the pull-down complex to a magnet once or multiple times. In some embodiments, the separation of the pull-down complex may include exposing the pull-down complex to a magnet once or multiple times, wherein each exposure is about 1 minute. In some embodiments, the separation of the pull-down complex may include exposing the pull-down complex to a magnet twice, wherein each exposure is about 1 minute. In some embodiments, the separation of the pull-down complex may include exposing the pull-down complex to a magnet three times, wherein each exposure is about 1 minute. In some embodiments, the separation of the pull-down complex may include incubating the pull-down complex with one or more wash buffers. In some embodiments, the separation of the pull-down complex may include incubating the pull-down complex with a wash buffer. In one embodiment, separation of the pull-down complex may include incubating the pull-down complex with two wash buffers. In another embodiment, the pull-down complex is incubated with the wash buffer for 5 minutes. In yet another embodiment, the pull-down complex is incubated with one or more wash buffers, with each incubation lasting 5 minutes. In yet another embodiment, the pull-down complex is incubated with the wash buffer at 68°C. In yet another embodiment, the pull-down complex is incubated with the wash buffer at 48°C.

[0088] In some embodiments, the method optionally includes a fifth step: eluting the target polynucleotide from the pull-down complex. In some embodiments, the optional fifth step includes eluting the adaptor-target polynucleotide from the pull-down complex. In some embodiments, eluting the adaptor-target polynucleotide from the pull-down complex may include incubation for about 5 minutes. In some embodiments, eluting the adaptor-target polynucleotide from the pull-down complex may include incubation at room temperature (RT).

[0089] In some embodiments, the method includes a sixth step: second-strand synthesis. In some embodiments, the sixth step includes synthesizing a complementary adaptor-target polynucleotide. In some embodiments, the pull-down complex or eluted adaptor-target polynucleotide is contacted with a polymerase under conditions that promote the production of the complementary adaptor-target polynucleotide. In some embodiments, the complementary adaptor-target polynucleotide contains a 3' protecting group. In some embodiments, the 3' protecting group prevents the sequencing of the synthesized complementary adaptor-target polynucleotide. In some embodiments, the synthesized complementary adaptor-target polynucleotide contains a 5' protecting group. In some embodiments, the 5' protecting group prevents the sequencing of the synthesized complementary adaptor-target polynucleotide.

[0090] In some embodiments, the method includes a seventh step: forming a sequencing complex. In some embodiments, the seventh step includes ligating a sequencing adaptor to an adaptor-target polynucleotide to form a sequencing complex. In some embodiments, a 3' protecting group prevents the ligation of the sequencing adaptor to the complementary adaptor-target polynucleotide. In some embodiments, a 5' protecting group prevents the ligation of the sequencing adaptor to the complementary adaptor-target polynucleotide. In some embodiments, a primer without a 5' is used to prevent the ligation of the sequencing adaptor to the complementary adaptor-target polynucleotide.

[0091] In some implementations, the method includes an eighth step: sequencing the sequencing complex. In some implementations, the complementary adaptor-target polynucleotide is not sequenced.

[0092] In another aspect, a method for detecting base modifications in a target polynucleotide is provided, the method comprising: (a) contacting the target polynucleotide with the one or more intransitive protons in the presence of a first ligase to generate an intransitive-target polynucleotide, wherein the one or more intransitive protons contain a primer binding site; (b) contacting the intransitive-target polynucleotide with the one or more tags to generate a tagged intransitive-target polynucleotide, wherein the one or more tags are complementary to one or more regions of the target polynucleotide; and (c) contacting the tagged intransitive-target polynucleotide with a solid support to promote hybridization of the one or more tags. (d) generating a pull-down complex; (e) eluting the pull-down complex; (f) optionally eluting the adaptor-target polynucleotide from the pull-down complex; (g) contacting the pull-down complex or the eluted adaptor-target polynucleotide with a first polymerase under conditions that promote the generation of a complementary adaptor-target polynucleotide, wherein the complementary adaptor-target polynucleotide contains a 3' or 5' protecting group; (g) in the presence of a second ligase, contacting the adaptor-target polynucleotide with the sequencing adaptor under conditions that promote the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex; and (h) sequencing the sequencing complex, wherein the sequencing includes sequencing the target polynucleotide sequence without sequencing the complementary adaptor-target polynucleotide, thereby detecting the base modification in the target polynucleotide.

[0093] In another aspect, a method for sequencing a target polynucleotide is provided, the method comprising: (a) contacting the target polynucleotide with the one or more intransitive protons in the presence of a first ligase to generate an intransitive-target polynucleotide, wherein the one or more intransitive protons contain a primer binding site; (b) contacting the intransitive-target polynucleotide with the one or more tags to generate a tagged intransitive-target polynucleotide, wherein the one or more tags are complementary to one or more regions of the target polynucleotide; and (c) contacting the tagged intransitive-target polynucleotide with a solid support to generate a pull-down complex. d) separating the pull-down complex; (e) optionally eluting the adaptor-target polynucleotide from the pull-down complex; (f) contacting the pull-down complex or the eluted adaptor-target polynucleotide with a first polymerase under conditions that promote the generation of complementary adaptor-target polynucleotides, wherein the complementary adaptor-target polynucleotide contains a 3' or 5' protecting group; (g) in the presence of a second ligase, contacting the adaptor-target polynucleotide with the sequencing adaptor under conditions that promote the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex; and (h) sequencing the sequencing complex, wherein the sequencing includes sequencing the target polynucleotide sequence without sequencing the complementary adaptor-target polynucleotide, thereby sequencing the target polynucleotide, wherein optionally the target polynucleotide contains one or more base modifications.

[0094] In one aspect, a method for quantifying base modifications in a target polynucleotide is provided, the method comprising: (a) contacting the target polynucleotide with the one or more intransitive protons in the presence of a first ligase to generate an intransitive-target polynucleotide, wherein the one or more intransitive protons contain a primer binding site; (b) contacting the intransitive-target polynucleotide with the one or more tags to generate a tagged intransitive-target polynucleotide, wherein the one or more tags are complementary to one or more regions of the target polynucleotide; and (c) contacting the tagged intransitive-target polynucleotide with a solid support to promote hybridization of the one or more tags. (d) generating a pull-down complex; (e) isolating the pull-down complex; (f) optionally eluting the adaptor-target polynucleotide from the pull-down complex; (g) contacting the pull-down complex or the eluted adaptor-target polynucleotide with a first polymerase under conditions that promote the generation of a complementary adaptor-target polynucleotide, wherein the complementary adaptor-target polynucleotide contains a 3' or 5' protecting group; (g) in the presence of a second ligase, contacting the adaptor-target polynucleotide with the sequencing adaptor under conditions that promote the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex; and (h) sequencing the sequencing complex, wherein the sequencing includes sequencing the target polynucleotide sequence without sequencing the complementary adaptor-target polynucleotide, thereby quantifying the base modification in the target polynucleotide.

[0095] In another aspect, a method is provided for detecting multiple base modifications in a plurality of target polynucleotides, the method comprising: (a) contacting the plurality of target polynucleotides with the one or more in the presence of a first ligase, under conditions that promote the ligation of one or more introducing agents to the plurality of target polynucleotides, to generate a plurality of introducing agent-target polynucleotides, wherein the one or more introducing agents contain primer binding sites; (b) contacting the plurality of introducing agent-target polynucleotides with the one or more introducing agents, under conditions that promote the hybridization of one or more tags to the plurality of introducing agent-target polynucleotides, to generate a plurality of tagged introducing agent-target polynucleotides, wherein the one or more tags are complementary to one or more regions of the plurality of target polynucleotides; and (c) contacting the plurality of tagged introducing agent-target polynucleotides with a solid support, under conditions that promote the hybridization of the one or more tags to a solid support, to generate a plurality of pull-downs. (d) separating the plurality of pull-down complexes; (e) optionally eluting the plurality of adaptor-target polynucleotides from the plurality of pull-down complexes; (f) contacting the plurality of pull-down complexes or the plurality of eluted adaptor-target polynucleotides with a first polymerase under conditions that promote the generation of a plurality of complementary adaptor-target polynucleotides, wherein each of the complementary adaptor-target polynucleotides contains a 3' or 5' protecting group; (g) in the presence of a second ligase, contacting the plurality of adaptor-target polynucleotides with the plurality of sequencing adaptors under conditions that promote the ligation of a plurality of sequencing adaptors to the plurality of adaptor-target polynucleotides to generate a plurality of sequencing complexes; and (h) sequencing the plurality of sequencing complexes, wherein the sequencing includes sequencing the plurality of target polynucleotide sequences without sequencing the plurality of complementary adaptor-target polynucleotides, thereby detecting a plurality of base modifications in the plurality of target polynucleotides.

[0096] In another aspect, a method for sequencing multiple target polynucleotides is provided, the method comprising: (a) contacting the multiple target polynucleotides with the one or more insulators in the presence of a first ligase, under conditions that promote the ligation of one or more insulators to the multiple target polynucleotides to generate multiple insulator-target polynucleotides, wherein the one or more insulators contain primer binding sites; (b) contacting the multiple insulator-target polynucleotides with the one or more tags in conditions that promote hybridization of one or more tags to the multiple insulator-target polynucleotides to generate multiple tagged insulator-target polynucleotides, wherein the one or more tags are complementary to one or more regions of the multiple target polynucleotides; (c) contacting the multiple tagged insulator-target polynucleotides with a solid support in conditions that promote hybridization of the one or more tags to the solid support to generate multiple pull-down complexes; and (d) separating the multiple insulator-target polynucleotides. (e) optionally eluting the plurality of adaptor-target polynucleotides from the plurality of pull-down complexes; (f) contacting the plurality of pull-down complexes or the plurality of eluted adaptor-target polynucleotides with a first polymerase under conditions that promote the generation of a plurality of complementary adaptor-target polynucleotides, wherein each of the complementary adaptor-target polynucleotides contains a 3' protecting group or a 5' protecting group; (g) in the presence of a second ligase, contacting the plurality of adaptor-target polynucleotides with the plurality of sequencing adaptors under conditions that promote the ligation of a plurality of sequencing adaptors to the plurality of adaptor-target polynucleotides to generate a plurality of sequencing complexes; and (h) sequencing the plurality of sequencing complexes, wherein the sequencing includes sequencing the plurality of target polynucleotide sequences without sequencing the plurality of complementary adaptor-target polynucleotides, thereby sequencing the plurality of target polynucleotides, wherein optionally the plurality of target polynucleotides contains one or more base modifications.

[0097] In another aspect, a method for detecting multiple base modifications in a target polynucleotide is provided, the method comprising: (a) contacting the target polynucleotide with the one or more intransitive protons in the presence of a first ligase to generate an intransitive-target polynucleotide, wherein the one or more intransitive protons contain a primer binding site; (b) contacting the intransitive-target polynucleotide with the one or more tags to generate a tagged intransitive-target polynucleotide, wherein the one or more tags are complementary to one or more regions of the target polynucleotide; and (c) contacting the tagged intransitive-target polynucleotide with a solid support to promote hybridization of the one or more tags. (d) generating a pull-down complex; (e) eluting the pull-down complex; (f) optionally eluting the adaptor-target polynucleotide from the pull-down complex; (g) contacting the pull-down complex or the eluted adaptor-target polynucleotide with a first polymerase under conditions that promote the generation of a complementary adaptor-target polynucleotide, wherein the complementary adaptor-target polynucleotide contains a 3' or 5' protecting group; (g) in the presence of a second ligase, contacting the adaptor-target polynucleotide with the sequencing adaptor under conditions that promote the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex; and (h) sequencing the sequencing complex, wherein the sequencing includes sequencing the target polynucleotide sequence without sequencing the complementary adaptor-target polynucleotide, thereby detecting the plurality of base modifications in the target polynucleotide.

[0098] In another aspect, a method for detecting base modifications in a plurality of target polynucleotides is provided, the method comprising: (a) contacting the plurality of target polynucleotides with the one or more in the presence of a first ligase, under conditions that promote the ligation of one or more introducing agents to the plurality of target polynucleotides, to generate a plurality of introducing agent-target polynucleotides, wherein the one or more introducing agents contain primer binding sites; (b) contacting the plurality of introducing agent-target polynucleotides with the one or more introducing agents, under conditions that promote the hybridization of one or more tags to the plurality of introducing agent-target polynucleotides, to generate a plurality of tagged introducing agent-target polynucleotides, wherein the one or more tags are complementary to one or more regions of the plurality of target polynucleotides; and (c) contacting the plurality of tagged introducing agent-target polynucleotides with a solid support, under conditions that promote the hybridization of the one or more tags to a solid support, to generate a plurality of pull-downs. (d) separating the plurality of pull-down complexes; (e) optionally eluting the plurality of adaptor-target polynucleotides from the plurality of pull-down complexes; (f) contacting the plurality of pull-down complexes or the plurality of eluted adaptor-target polynucleotides with a first polymerase under conditions that promote the generation of a plurality of complementary adaptor-target polynucleotides, wherein each of the complementary adaptor-target polynucleotides contains a 3' or 5' protecting group; (g) in the presence of a second ligase, contacting the plurality of adaptor-target polynucleotides with the plurality of sequencing adaptors under conditions that promote the ligation of a plurality of sequencing adaptors to the plurality of adaptor-target polynucleotides to generate a plurality of sequencing complexes; and (h) sequencing the plurality of sequencing complexes, wherein the sequencing includes sequencing the plurality of target polynucleotide sequences without sequencing the plurality of complementary adaptor-target polynucleotides, thereby detecting base modifications in the plurality of target polynucleotides.

[0099] In embodiments, conditions for promoting the ligation of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide include providing a first ligase, one or more adaptors, and a target polynucleotide in a suitable buffer and at a suitable temperature. In embodiments, the buffer contains suitable components (e.g., pH, ionic strength, cofactors, etc.) for promoting the ligation of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide. In embodiments, conditions for promoting the ligation of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include one or more adaptors. In embodiments, conditions for promoting the ligation of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include one or more barcodes. In embodiments, conditions for promoting the ligation of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include a ligation enhancer. In embodiments, conditions for promoting the ligation of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include a first ligase. In embodiments, conditions for promoting the ligation of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include T4 DNA ligase. In embodiments, conditions for promoting the ligation of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include polyethylene glycol (PEG). In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include adenosine triphosphate (ATP). In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at room temperature (RT). In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation for approximately 15 minutes.

[0100] In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 17°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 18°C ​​to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 19°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 20°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 21°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 22°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 23°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 24°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 25°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 26°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 27°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 28°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 29°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 30°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 31°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 32°C to about 37°C.In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 33°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 34°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 35°C to about 37°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 36°C to about 37°C.

[0101] In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 36°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 35°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 34°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 33°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 32°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 31°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 30°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 29°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 28°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 27°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 26°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 25°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 24°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 23°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 22°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 21°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 20°C.In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 19°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 16°C to about 18°C. In some embodiments, conditions for promoting the linkage of one or more adaptors to a target polynucleotide to generate an adaptor-target polynucleotide may include incubation at about 17°C to about 36°C.

[0102] In embodiments, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide include providing one or more tags and an adaptor-target polynucleotide in a suitable buffer and at a suitable temperature. In embodiments, the buffer contains suitable components (e.g., pH, ionic strength, cofactors, etc.) for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide. In embodiments, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include a hybridization enhancer. In embodiments, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include a synthetic polynucleotide. In embodiments, the synthetic polynucleotide prevents nonspecific binding. In embodiments, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include a nonspecifically synthesized polynucleotide. In embodiments, the nonspecifically synthesized polynucleotide prevents nonspecific binding. In embodiments, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include DNA from a species different from the target polynucleotide. In one embodiment, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include salmon sperm DNA. In another embodiment, salmon sperm DNA prevents nonspecific binding. In yet another embodiment, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include incubation at approximately 70°C. In yet another embodiment, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include incubation for approximately 20 hours.

[0103] In some embodiments, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include incubation at about 50°C to about 80°C. In some embodiments, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include incubation at about 55°C to about 80°C. In some embodiments, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include incubation at about 60°C to about 80°C. In some embodiments, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include incubation at about 65°C to about 80°C. In some embodiments, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include incubation at about 70°C to about 80°C. In the implementation scheme, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include incubation at about 75°C to about 80°C.

[0104] In some embodiments, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include incubation at about 50°C to about 75°C. In some embodiments, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include incubation at about 50°C to about 70°C. In some embodiments, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include incubation at about 50°C to about 65°C. In some embodiments, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include incubation at about 50°C to about 60°C. In some embodiments, conditions for promoting hybridization of one or more tags with an adaptor-target polynucleotide to produce a tagged adaptor-target polynucleotide may include incubation at about 50°C to about 55°C.

[0105] In one embodiment, conditions for promoting hybridization of one or more tags with a solid support to generate a pull-down complex include providing one or more tags and a solid support that bind to the adaptor-target polynucleotide in an appropriate buffer and at a suitable temperature. In another embodiment, the buffer contains appropriate components (e.g., pH, ionic strength, cofactors, etc.) for promoting hybridization of one or more tags with a solid support to generate a pull-down complex. In yet another embodiment, conditions for promoting hybridization of one or more tags with a solid support to generate a pull-down complex may include incubation at approximately 68°C. In yet another embodiment, conditions for promoting hybridization of one or more tags with a solid support to generate a pull-down complex may include incubation for approximately 5 minutes.

[0106] In embodiments, conditions promoting the production of complementary adaptor-target polynucleotides include providing nucleotide triphosphates and polymerases (e.g., thermostable polymerases) in an appropriate buffer and at a suitable temperature. In embodiments, the buffer contains appropriate components that promote nucleic acid synthesis (e.g., pH, ionic strength, cofactors, etc.). In embodiments, conditions promoting the production of complementary adaptor-target polynucleotides may include standard polymerase chain reaction conditions. In embodiments, conditions promoting the production of complementary adaptor-target polynucleotides may include incubation at approximately 60°C. In embodiments, conditions promoting the production of complementary adaptor-target polynucleotides may include incubation for approximately 15 minutes. In embodiments, conditions promoting the production of complementary adaptor-target polynucleotides may include polyethylene glycol (PEG). In embodiments, conditions promoting the production of complementary adaptor-target polynucleotides may include adenosine triphosphate (ATP). In embodiments, conditions promoting the production of complementary adaptor-target polynucleotides may include... Bst 3.0 DNA polymerase. In some embodiments, conditions promoting the generation of complementary adaptor-target polynucleotides may include BST buffer. In some embodiments, conditions promoting the generation of complementary adaptor-target polynucleotides may include elution primers. In some embodiments, conditions promoting the generation of complementary adaptor-target polynucleotides may include one or more free nucleotides. In some embodiments, conditions promoting the generation of complementary adaptor-target polynucleotides may include one or more deoxynucleotide triphosphates. In some embodiments, conditions promoting the generation of complementary adaptor-target polynucleotides may include MgSO4.

[0107] In embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex include providing a second ligase, the sequencing adaptor, and the adaptor-target polynucleotide in an appropriate buffer and at a suitable temperature. In embodiments, the buffer contains appropriate components (e.g., pH, ionic strength, cofactors, etc.) for promoting the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex. In embodiments, conditions for promoting the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex may include incubation for approximately 15 minutes. In embodiments, conditions for promoting the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex may include incubation at room temperature (RT). In embodiments, conditions for promoting the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex may include ligation adaptor (LA). In embodiments, conditions for promoting the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex may include ligation buffer (LNB). In embodiments, conditions for promoting the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex may include a quick ligase. In the implementation scheme, the conditions that facilitate the ligation of sequencing adaptors to adaptor-target polynucleotides to produce sequencing complexes may include a fast T4 ligase.

[0108] In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 37°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 17°C to about 37°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 18°C ​​to about 37°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 19°C to about 37°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 20°C to about 37°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 21°C to about 37°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 22°C to about 37°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 23°C to about 37°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 24°C to about 37°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 25°C to about 37°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 26°C to about 37°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 27°C to about 37°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 28°C to about 37°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 29°C to about 37°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 30°C to about 37°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 31°C to about 37°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 32°C to about 37°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 33°C to about 37°C.In one embodiment, conditions for promoting the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 34°C to about 37°C. In another embodiment, conditions for promoting the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 35°C to about 37°C. In yet another embodiment, conditions for promoting the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 36°C to about 37°C.

[0109] In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 36°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 35°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 34°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 33°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 32°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 31°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 30°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 29°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 28°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 27°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 26°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 25°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 24°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 23°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 22°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 21°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 20°C. In some embodiments, conditions for promoting the ligation of a sequencing adaptor to an adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 19°C.In one embodiment, conditions for promoting the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 18°C. In another embodiment, conditions for promoting the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex may include incubation at about 16°C to about 17°C.

[0110] In some implementations, the method further includes: (i) analyzing the sequenced sequencing complex to detect base modifications.

[0111] In some implementations, the method further includes repeating steps (a) to (i) at least once using one or more additional connectors.

[0112] In some embodiments, the target polynucleotide is isolated from the biological sample prior to step (a). In these embodiments, the biological sample is derived from a human.

[0113] In some embodiments, the target polynucleotide includes genomic DNA (gDNA) or cell-free DNA (cfDNA).

[0114] In some embodiments, the target polynucleotide is fragmented prior to step (a). In some embodiments, fragmentation includes mechanical fragmentation or enzymatic fragmentation. In some embodiments, fragmentation includes mechanical fragmentation. In some embodiments, mechanical fragmentation includes focused acoustic shearing, hydrodynamic shearing, or nebulization. In some embodiments, mechanical fragmentation includes focused acoustic shearing. In some embodiments, mechanical fragmentation includes hydrodynamic shearing. In some embodiments, mechanical fragmentation includes nebulization. In some embodiments, fragmentation includes enzymatic fragmentation. In some embodiments, enzymatic fragmentation includes transposases, restriction enzymes, or nonspecific nicking enzymes. In some embodiments, enzymatic fragmentation includes transposases. In some embodiments, enzymatic fragmentation includes restriction enzymes. In some embodiments, enzymatic fragmentation includes nonspecific nicking enzymes.

[0115] In some embodiments, the target polynucleotide fragment is between about 75 base pairs (bp) and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 100 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 125 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 150 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 175 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 200 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 300 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 400 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 500 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 600 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 700 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 800 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 900 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 1000 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 2000 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 3000 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 4000 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 5000 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 6000 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 7000 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 8000 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 9000 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 10,000 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 15,000 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 20,000 bp and about 50,000 bp.In some embodiments, the target polynucleotide fragment is between about 25,000 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 30,000 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 35,000 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 40,000 bp and about 50,000 bp. In some embodiments, the target polynucleotide fragment is between about 45,000 bp and about 50,000 bp.

[0116] In some embodiments, the target polynucleotide fragment is between about 75 bp and about 45,000 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 40,000 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 35,000 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 30,000 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 25,000 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 20,000 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 15,000 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 10,000 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 9,000 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 8,000 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 7,000 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 6,000 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 5,000 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 4,000 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 3,000 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 2,000 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 1,000 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 900 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 800 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 700 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 600 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 500 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 400 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 300 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 200 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 175 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 150 bp. In some embodiments, the target polynucleotide fragment is between about 75 bp and about 125 bp.In some implementations, the target polynucleotide fragment is between approximately 75 bp and approximately 100 bp.

[0117] In some embodiments, the target polynucleotide fragment is between 75 base bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 100 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 125 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 150 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 175 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 200 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 300 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 400 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 500 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 600 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 700 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 800 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 900 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 1000 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 2000 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 3000 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 4000 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 5000 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 6000 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 7000 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 8000 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 9000 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 10,000 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 15,000 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 20,000 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 25,000 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 30,000 bp and 50,000 bp.In some embodiments, the target polynucleotide fragment is between 35,000 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 40,000 bp and 50,000 bp. In some embodiments, the target polynucleotide fragment is between 45,000 bp and 50,000 bp.

[0118] In some embodiments, the target polynucleotide fragment is between 75 bp and 45,000 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 40,000 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 35,000 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 30,000 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 25,000 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 20,000 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 15,000 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 10,000 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 9,000 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 8,000 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 7,000 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 6,000 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 5,000 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 4,000 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 3,000 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 2,000 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 1,000 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 900 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 800 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 700 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 600 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 500 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 400 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 300 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 200 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 175 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 150 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 125 bp. In some embodiments, the target polynucleotide fragment is between 75 bp and 100 bp.

[0119] In some implementations, one or more connectors also include a first barcode.

[0120] In some implementations, one or more additional connectors may also include one or more additional barcodes.

[0121] In some embodiments, one or more tags contain half of a homologous pair. In some embodiments, one or more tags contain one or more binding moieties. In some embodiments, one or more tags contain streptavidin, biotin, maltose, maltose-binding protein, glutathione, glutathione S-transferase, chitin, chitin-binding protein, aptamer, antigen, SpyCatcher, SpyTag, or antibody. In some embodiments, one or more tags contain streptavidin. In some embodiments, one or more tags contain biotin. In some embodiments, one or more tags contain maltose. In some embodiments, one or more tags contain maltose-binding protein. In some embodiments, one or more tags contain glutathione. In some embodiments, one or more tags contain glutathione S-transferase. In some embodiments, one or more tags contain chitin. In some embodiments, one or more tags contain chitin-binding protein. In some embodiments, one or more tags contain aptamers. In some embodiments, one or more tags contain antigens. In some embodiments, one or more tags contain SpyCatcher. In some embodiments, one or more tags contain SpyTag. In some embodiments, one or more tags contain antibodies.

[0122] In some implementations, one or more tags target the same region of the target polynucleotide.

[0123] In some implementations, one or more tags target different regions of the target polynucleotide.

[0124] In some embodiments, the solid support comprises half of a homology pair. In some embodiments, the solid support comprises a capture portion. In some embodiments, the solid support comprises streptavidin, biotin, maltose, maltose-binding protein, glutathione, glutathione S-transferase, chitin, chitin-binding protein, aptamer, antigen, SpyCatcher, SpyTag, or antibody. In some embodiments, the solid support comprises streptavidin. In some embodiments, the solid support comprises biotin. In some embodiments, the solid support comprises maltose. In some embodiments, the solid support comprises maltose-binding protein. In some embodiments, the solid support comprises glutathione. In some embodiments, the solid support comprises glutathione S-transferase. In some embodiments, the solid support comprises chitin. In some embodiments, the solid support comprises chitin-binding protein. In some embodiments, the solid support comprises aptamer. In some embodiments, the solid support comprises antigen. In some embodiments, the solid support comprises SpyCatcher. In some embodiments, the solid support contains a SpyTag. In some embodiments, the solid support contains an antibody.

[0125] In some embodiments, the solid support comprises beads or pillars. In some embodiments, the solid support is beads. In some embodiments, the solid support is pillars. In some embodiments, the beads are paramagnetic.

[0126] In some embodiments, elution in step (e) includes separating the intransitive target polynucleotide from one or more tags, thereby separating the intransitive target polynucleotide from the solid support. In some embodiments, the separation in step (e) includes denaturing one or more tags. In some embodiments, denaturation of one or more tags causes one or more tags to decompress, thereby separating the intransitive target polynucleotide from the solid support. In some embodiments, the separation in step (e) includes displacing one or more tags from the intransitive target polynucleotide using a chain displacement polymerase, thereby separating the intransitive target polynucleotide from the solid support. In some embodiments, the separation in step (e) includes digesting one or more tags with a polymerase having exonuclease activity, thereby separating the intransitive target polynucleotide from the solid support.

[0127] In some embodiments, the elution of step (e) includes NaOH, heat, chain displacement polymerase, or a polymerase with exonuclease activity. In some embodiments, the elution step (e) includes alkali. In some embodiments, the elution of step (e) may include incubation with alkali for about 5 minutes. In some embodiments, the elution of step (e) may include incubation with alkali at room temperature (RT). In some embodiments, the elution of step (e) includes NaOH. In some embodiments, the elution of step (e) may include incubation with NaOH for about 5 minutes. In some embodiments, the elution of step (e) may include incubation with NaOH at room temperature (RT). In some embodiments, the elution of step (e) includes heating. In some embodiments, the elution of step (e) includes chain displacement polymerase. In some embodiments, the elution of step (e) includes a polymerase with exonuclease activity.

[0128] In some embodiments, the 3' protecting group prevents sequencing of the complementary adaptor-target polynucleotide. In some embodiments, the 3' protecting group includes a nucleotide overhang. In some embodiments, the nucleotide overhang comprises at least one nucleotide, two nucleotides, or three nucleotides. In some embodiments, the nucleotide overhang comprises at least one nucleotide. In some embodiments, the nucleotide overhang comprises at least two nucleotides. In some embodiments, the nucleotide overhang comprises at least three nucleotides.

[0129] In some embodiments, the 5' protecting group prevents sequencing of the complementary adaptor-target polynucleotide. In some embodiments, the 5' protecting group comprises an aldehyde. In some embodiments, the 5' protecting group comprises an amine. In some embodiments, the 5' protecting group comprises a thiol.

[0130] In some implementations, the primers do not contain a 5' phosphate group.

[0131] In some implementations, the sequencing adaptor contains a second barcode.

[0132] In some embodiments, the base modification includes 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), N6-methyladenine (6mA), 7-methylguanine (m7G), 2'-O-methylation (2'-O-methyl), or bromodeoxyuridine (BrdU). In some embodiments, the base modification includes 5-methylcytosine (5mC). In some embodiments, the base modification includes 5-hydroxymethylcytosine (5hmC). In some embodiments, the base modification includes N6-methyladenine (6mA). In some embodiments, the base modification includes 7-methylguanine (m7G). In some embodiments, the base modification includes 2'-O-methylation (2'-O-methyl). In some embodiments, the base modification includes bromodeoxyuridine (BrdU).

[0133] In some embodiments, the multiple base modifications include one or more of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), N, 6-methyladenine (6mA), 7-methylguanine (m7G), 2'-O-methylation (2'-O-methyl), or bromodeoxyuridine (BrdU). In some embodiments, the multiple base modifications include 5-methylcytosine (5mC). In some embodiments, the multiple base modifications include 5-hydroxymethylcytosine (5hmC). In some embodiments, the multiple base modifications include N, 6-methyladenine (6mA). In some embodiments, the multiple base modifications include 7-methylguanine (m7G). In some embodiments, the multiple base modifications include 2'-O-methylation (2'-O-methyl). In some embodiments, the multiple base modifications include bromodeoxyuridine (BrdU).

[0134] In some embodiments, the method does not include bisulfite conversion or amplification of the target polynucleotide.

[0135] In some implementations, the method does not include reduced representative bisulfite sequencing (RRBS) or reduced representative methylation sequencing (RRMS).

[0136] In some embodiments, the first or second ligase is a T4 DNA ligase, a rapid ligase, a T3 ligase, a T7 ligase, or a tag ligase. In some embodiments, the first or second ligase is a T4 DNA ligase. In some embodiments, the first or second ligase is a rapid ligase. In some embodiments, the first or second ligase is a T3 ligase. In some embodiments, the first or second ligase is a T7 ligase. In some embodiments, the first or second ligase is a tag ligase.

[0137] In some embodiments, the first ligase is a T4 DNA ligase, a rapid ligase, a T3 ligase, a T7 ligase, or a tag ligase. In some embodiments, the first ligase is a T4 DNA ligase. In some embodiments, the first ligase is a rapid ligase. In some embodiments, the first ligase is a T3 ligase. In some embodiments, the first ligase is a T7 ligase. In some embodiments, the first ligase is a tag ligase.

[0138] In some embodiments, the second ligase is a T4 DNA ligase, a rapid ligase, a T3 ligase, a T7 ligase, or a tag ligase. In some embodiments, the second ligase is a T4 DNA ligase. In some embodiments, the second ligase is a rapid ligase. In some embodiments, the second ligase is a T3 ligase. In some embodiments, the second ligase is a T7 ligase. In some embodiments, the second ligase is a tag ligase.

[0139] In some embodiments, the first polymerase is Taq polymerase, BST polymerase, sulfolobus polymerase, thermominator polymerase, Kleno polymerase, or deep vent polymerase. In some embodiments, the first polymerase is Taq polymerase. In some embodiments, the first polymerase is BST polymerase. In some embodiments, the first polymerase is sulfolobus polymerase. In some embodiments, the first polymerase is thermominator polymerase. In some embodiments, the first polymerase is Kleno polymerase. In some embodiments, the first polymerase is deep vent polymerase.

[0140] In some implementations, sequencing is performed on a sequencer capable of identifying the modified bases.

[0141] In some implementations, the base modifications in the target polynucleotide are preserved until sequencing.

[0142] In some embodiments, this method enriches the base modifications of the target polynucleotide by approximately 300-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of the target polynucleotide by approximately 400-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of the target polynucleotide by approximately 500-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of the target polynucleotide by approximately 600-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of the target polynucleotide by approximately 700-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of the target polynucleotide by approximately 800-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of the target polynucleotide by approximately 900-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 1000-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 1100-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 1200-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 1300-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 1400-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 1500-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 1600-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by approximately 1700-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by approximately 1800-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by approximately 1900-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by approximately 2000-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by approximately 2100-fold to approximately 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by approximately 2200-fold to approximately 2400-fold compared to whole-genome sequencing.In some implementations, this method enriches the base modifications in target polynucleotides by approximately 2300-fold to approximately 2400-fold compared to whole-genome sequencing.

[0143] In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 300-fold to approximately 2300-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 300-fold to approximately 2200-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 300-fold to approximately 2100-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 300-fold to approximately 2000-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 300-fold to approximately 1900-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 300-fold to approximately 1800-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 300-fold to approximately 1700-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 300-fold to approximately 1600-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 300-fold to approximately 1500-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 300-fold to approximately 1400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 300-fold to approximately 1300-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 300-fold to approximately 1200-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 300-fold to approximately 1100-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by approximately 300-fold to approximately 1000-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by approximately 300-fold to approximately 900-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by approximately 300-fold to approximately 800-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by approximately 300-fold to approximately 700-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by approximately 300-fold to approximately 600-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by approximately 300-fold to approximately 500-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by approximately 300-fold to approximately 400-fold compared to whole-genome sequencing.

[0144] In some embodiments, this method enriches the base modifications in target polynucleotides by 300-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 400-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 500-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 600-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 700-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 800-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 900-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 1000-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 1100-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 1200-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 1300-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 1400-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 1500-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 1600-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 1700-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 1800-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 1900-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 2000-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 2100-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 2200-fold to 2400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 2300-fold to 2400-fold compared to whole-genome sequencing.

[0145] In some embodiments, this method enriches the base modifications in target polynucleotides by 300-fold to 2300-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 300-fold to 2200-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 300-fold to 2100-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 300-fold to 2000-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 300-fold to 1900-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 300-fold to 1800-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 300-fold to 1700-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 300-fold to 1600-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 300-fold to 1500-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 300-fold to 1400-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 300-fold to 1300-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 300-fold to 1200-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 300-fold to 1100-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications in target polynucleotides by 300-fold to 1000-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by 300-fold to 900-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by 300-fold to 800-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by 300-fold to 700-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by 300-fold to 600-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by 300-fold to 500-fold compared to whole-genome sequencing. In some embodiments, this method enriches the base modifications of target polynucleotides by 300-fold to 400-fold compared to whole-genome sequencing.

[0146] Example Those skilled in the art will understand that the examples described herein are for illustrative purposes only, and this disclosure is not limited thereto.

[0147] Example 1. We have developed a novel method for isolating specific regions of the genome using oligonucleotide hybridization pull-down, enabling direct identification of modified bases from the pull-down products. The key innovation lies in generating a second strand after hybridization, which is configured to allow only one end of the adaptor to be attached. This restricts sequencing to the native strand, i.e., the only strand with the potential modification. Therefore, our process efficiently utilizes the maximum number of sequencing reads.

[0148] We have simplified this approach to practice using a library of polynucleotides targeting 1,235 2-kb regions of the genome, whose methylation patterns can be used to assess sperm quality. The protocol used is attached. CpG loci in each region were then evaluated to quantify their methylation fractions. The methylation fractions ranged from 0 (completely unmethylated) to 1 (completely methylated; Fig. 2A) and correlated with typical results obtained using the MethylationEpic array (Fig. 2B) (a common method for identifying methylated cytosine). This finding supports our assumption that we only sequenced the natural strand. It would be impossible to obtain fully methylated (methylation fraction of 1) CpGs if we sequenced both the natural and synthetic strands, as the synthetic strand is always completely unmethylated. However, we obtained over 800 fully methylated sites. To more fully confirm that we only sequenced the natural strand, we also searched the sequencing reads for the reverse complement sequence of the nanopore ligation sequencing kit (SQK-LSK114) adaptor. The presence of the adaptor indicates that both ends of the enriched DNA have been joined, allowing sequencing of both the natural and synthetic strands. While we identified forward adaptor sequences in >85,000 sequences, no reverse complementary sequences were found. In summary, these results demonstrate that our method, which sequences only the natural strand, can identify a full range of base modification states, produces results consistent with other methods, and provides high-quality data due to the potential for significantly longer reads.

[0149] Example 2. Materials and Methods Sample preparation and barcoding.Extracted DNA (1.5 μg) was fragmented, repaired, and end-prepared using the Ultra II FS DNA module (NEB). The DNA was then purified using Ampure XP beads (Beckman Coulter) at a 0.8× ratio, following the manufacturer's instructions. The DNA fragment (750 ng) was mixed with 100 pmol of an adaptor containing a 3'T overhang, a 20-base-pair sequence for sample identification, and a 30-base-pair primer binding site, and ligated at room temperature with an inert / TA Mastermix (NEB) for 15 minutes. The reaction was then stopped using 0.5 M EDTA.

[0150] Oligonucleotide hybridization. Following the manufacturer's recommendations, twelve barcoded samples were mixed and purified using Ampure XP beads at a 0.5× ratio, and eluted in 12 μL buffer containing the blocking agent and blocking agent solution. In another tube, 20 μL of the hybridization mixture was mixed with 100 ng of the oligonucleotide probe library, heated to 95°C and held for 2 minutes, then placed on ice. The eluted DNA fragments were then heated to 95°C and held for 5 minutes, and then both mixtures were allowed to return to room temperature and held for 5 minutes. The two mixtures were then combined, and a 30 μL layer of hybridization enhancer was plated onto the reaction mixture. The complete mixture was then incubated at 70°C for 20 hours.

[0151] The next day, the hybridization reaction mixture was transferred to streptavidin-conjugated beads and incubated at 68°C for 5 minutes. After four washes, the DNA was eluted from the beads in 0.1 N NaOH. The reaction was neutralized using 4 μL of 1 M Tris, pH 5.2.

[0152] Second-chain synthesis. The enriched DNA was mixed with 10 pmol of primers configured to bind to the 3' adaptor and prevent ligation to that end. The second strand was synthesized using BST 3.0, which can transpose any oligonucleotide probe still bound to DNA and generate a 3' A overhang. The reaction mixture was incubated at 60°C for 15 minutes to synthesize the second strand.

[0153] Library preparation. Nanopore sequencing libraries were created using a ligation sequencing kit (nanopore) with the following modifications: First, quantification was not performed because the amount of enriched DNA was below detection levels. Second, the adaptor was diluted 1:10 in 1X LNB buffer and then ligated. Finally, up to eight pull-down fragments were mixed into a single sequencing reaction.

[0154] Example 3. Prediction of Fertility Treatment Success Based on Methylation The embodiments described herein are methods for assessing the likelihood of a couple needing to conceive through in vitro fertilization (IVF) rather than intrauterine insemination (IUI) or timed intercourse. This is entirely based on targeted sequencing of sperm for genetic and epigenetic evaluation using the methods described herein. Our model generation yielded the following results in our test set (excluding model generation): PPV = 88.9 | NPV = 100 | Sensitivity = 100 | Specificity = 83.3 Importantly, when we tested the same model with known fertile sperm donors, we expected 15 out of 16 women to achieve pregnancy without IVF. The model currently used by Inherent is based on array data, which has far less information content or resolution than the model generated using the method described in this paper. Their results for the same 14 samples are as follows: Poor prediction quality (failure without IVF) – 1 in 2 women can achieve pregnancy without IVF.

[0155] Predictive quality is average (moderate success rate even without IVF) – 4 out of 8 women can achieve pregnancy without IVF.

[0156] High prediction quality (pregnancy possible without IVF) – 1 in 4 women will achieve pregnancy without IVF.

[0157] Compared to other tests currently on the market, analysis of data generated using the method described in this paper significantly improves results, and the same technique can be used to improve diagnostics in multiple spaces.

[0158] We collaborated with a company that developed a methylation array-based approach to predict whether artificial insemination is suitable for a particular patient. This assay observes the methylation status of CpG sites in a previously identified, informational 2-kbp region of sperm.

[0159] We created an oligonucleotide library to identify the same regions and used native methylation readout for Nanohyb enrichment and nanopore sequencing. The samples consisted of DNA from 24 patients with known treatment outcomes, which had previously been run using array methods. Run statistics are shown in Table 1 below.

[0160] Table 1. Operational statistics value Number of 2,000 bp regions (probes) 1,235 (4,940) Percentage of genomes in the region 0.07% Average number of reads for each sample (screened by quality and region) 183,088 Average percentage of reading segments in the area 57.7% Average enrichment 824x The methylation patterns were consistent with previous results (Figure 3A). Furthermore, the region methylation patterns were more consistent with the array (Figure 3B). The correlation between the array and sequencing improved when considering the average of the entire 2 kb region. However, we also found that performance could be obtained by observing the methylation of the entire read, which is not possible with the array.

[0161] Although the probe set was not designed to measure copy number variation (CNV), we decided to observe its measurability by measuring the average coverage of the probes along the chromosome. Chromosomal copy number was determined by averaging the read counts for each region of the entire chromosome and then normalizing to the average of all autosomes. The Y chromosome had 1 probe, the X chromosome had 28 probes, and the range for autosomes was 20 to 149 probes per chromosome. Although the range of probe numbers was wide, with only one probe on the Y chromosome, the copy number estimates were very accurate and remained stable across replicates (Figure 4).

[0162] Example 4. Detection of variants in genes that are difficult to sequence Most genes are considered "difficult to sequence" due to their high GC content, long length, repetitive regions, and the presence of similar genes or pseudogenes due to genomic duplication. A group of these genes has mutations that can lead to polycystic kidney disease (PKD): PKD1, PKD2, and PKHD1. Furthermore, multiple different mutations throughout the gene are associated with the disease, and the nature of the mutations and the gene itself has a significant impact on prognosis.

[0163] To demonstrate Nanohyb's ability to sequence these genes, we developed probe sets targeting these three genes and performed a pull-down analysis on individuals with known mutations in PKD2. The operational statistics are shown in Table 2 below.

[0164] Table 2. Operational statistics value Number of probes 1,421 Percentage of genomes in the region 0.015% Number of segments read in the zone (filtered by quality and zone) 4,038 Percentage of segments read in the area 35.4% Enrichment 2,360x Table 3. Nanohyb enrichment of long reads effectively distinguished repetitive genes. Pseudogenes had very few aligned reads compared to functional genes (bold). <![CDATA[ Gene ]]> <![CDATA[ Aligned segment count ]]> <![CDATA[ Gene ]]> <![CDATA[ Aligned segment count ]]> <![CDATA[ Gene ]]> <![CDATA[ Aligned segment count ]]> PKD1 (51.2 kb) 384 PKD2 (74.1 kb) 547 PKHD1 3,101 PKD1L1 0 PKD2L1 1 PKHD1L1 0 PKD1L2 1 PKD2L2 0 PKD1L3 0 PKD2L2-DT 0 PKD1P1 3 PKD1P3 3 PKD1P4 2 PKD1P5 8 PKD1P6 5 Example 5. Exemplary scheme for oligonucleotide hybridization enrichment for natural chain sequencing The plan is to spend 2.5 hours on the first day and 3 hours on the second day. surface Table 4: Enrichment of loci targeted by Nanohyb. Two oligonucleotide libraries were created, each targeting regions exhibiting unique methylation patterns in sperm and neuronal cells, respectively. The table shows the percentage of the genome covered by these regions and the average percentage of reads aligned with these regions (n=3). Fold enrichment is calculated by dividing the percentage of reads by the percentage of the targeted genome. Table 5: Cost comparison of enrichment methods allowing natural methylation interpretation on nanopores. Estimates are based on the following assumptions: 100,000 reads per sample region, 150 million reads per flow cell, and fold enrichment in the middle of the published range. Labor costs are estimated at $50 per hour, with Nanohyb requiring 8 hours of manual operation and the other two methods requiring 2 hours. Price estimates are calculated using pricing as of September 13, 2023. *Limited by the number of available barcodes; theoretical maximum of 480 samples per flow cell. References Implementation Plan Implementation Scheme 1. A method for detecting base modifications in a target polynucleotide, the method comprising: (a) contacting the target polynucleotide with the one or more intransitive protons in the presence of a first ligase to generate an intransitive-target polynucleotide, wherein the one or more intransitive protons contain a primer binding site; (b) contacting the intransitive-target polynucleotide with the one or more tags to generate a tagged intransitive-target polynucleotide, wherein the one or more tags are complementary to one or more regions of the target polynucleotide; and (c) contacting the tagged intransitive-target polynucleotide with a solid support to generate an intransitive-target polynucleotide. (d) generating a pull-down complex; (e) isolating the pull-down complex; (f) optionally eluting the adaptor-target polynucleotide from the pull-down complex; (g) contacting the pull-down complex or the eluted adaptor-target polynucleotide with a first polymerase under conditions that promote the generation of a complementary adaptor-target polynucleotide, wherein the complementary adaptor-target polynucleotide contains a 3' protecting group; (g) contacting the adaptor-target polynucleotide with the sequencing adaptor in the presence of a second ligase under conditions that promote the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex; and (h) sequencing the sequencing complex, wherein the sequencing includes sequencing the target polynucleotide sequence without sequencing the complementary adaptor-target polynucleotide, thereby detecting the base modification in the target polynucleotide.

[0165] Implementation Scheme 2. A method for sequencing a target polynucleotide, the method comprising: (a) contacting the target polynucleotide with the one or more intransitive protons in the presence of a first ligase to generate an intransitive-target polynucleotide, wherein the one or more intransitive protons contain a primer binding site; (b) contacting the intransitive-target polynucleotide with the one or more tags to generate a tagged intransitive-target polynucleotide, wherein the one or more tags are complementary to one or more regions of the target polynucleotide; (c) contacting the tagged intransitive-target polynucleotide with a solid support to generate a pull-down complex, wherein the one or more tags are hybridized to a solid support; (d) ... (e) Separating the pull-down complex; (f) optionally eluting the adaptor-target polynucleotide from the pull-down complex; (g) contacting the pull-down complex or the eluted adaptor-target polynucleotide with a first polymerase under conditions that promote the generation of complementary adaptor-target polynucleotides, wherein the complementary adaptor-target polynucleotide contains a 3' protecting group; (h) contacting the adaptor-target polynucleotide with the sequencing adaptor in the presence of a second ligase under conditions that promote the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex; and (h) sequencing the sequencing complex, wherein the sequencing includes sequencing the target polynucleotide sequence without sequencing the complementary adaptor-target polynucleotide, thereby sequencing the target polynucleotide, wherein optionally the target polynucleotide contains one or more base modifications.

[0166] Implementation Scheme 3. A method for quantifying base modifications in a target polynucleotide, the method comprising: (a) contacting the target polynucleotide with the one or more intransitive protons in the presence of a first ligase to generate an intransitive-target polynucleotide, wherein the one or more intransitive protons contain a primer binding site; (b) contacting the intransitive-target polynucleotide with the one or more tags to generate a tagged intransitive-target polynucleotide, wherein the one or more tags are complementary to one or more regions of the target polynucleotide; and (c) contacting the tagged intransitive-target polynucleotide with a solid support to generate a tagged intransitive-target polynucleotide. (d) Contacting the solid support to generate a pull-down complex; (e) separating the pull-down complex; (f) optionally eluting the adaptor-target polynucleotide from the pull-down complex; (g) contacting the pull-down complex or the eluted adaptor-target polynucleotide with a first polymerase under conditions that promote the generation of a complementary adaptor-target polynucleotide, wherein the complementary adaptor-target polynucleotide contains a 3' protecting group; (g) contacting the adaptor-target polynucleotide with the sequencing adaptor in the presence of a second ligase under conditions that promote the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex; and (h) sequencing the sequencing complex, wherein the sequencing includes sequencing the target polynucleotide sequence without sequencing the complementary adaptor-target polynucleotide, thereby quantifying the base modification in the target polynucleotide.

[0167] Implementation Scheme 4. A method for detecting multiple base modifications in multiple target polynucleotides, the method comprising: (a) in the presence of a first ligase, contacting the multiple target polynucleotides with the one or more initiators under conditions that promote the ligation of one or more initiators to the multiple target polynucleotides to generate multiple initiator-target polynucleotides, wherein the one or more initiators contain a primer binding site; (b) contacting the multiple initiator-target polynucleotides with the one or more tags under conditions that promote the hybridization of one or more tags to the multiple initiator-target polynucleotides to generate multiple tagged initiator-target polynucleotides, wherein the one or more tags are complementary to one or more regions of the multiple target polynucleotides; (c) contacting the multiple tagged initiator-target polynucleotides with the solid support under conditions that promote the hybridization of the one or more tags to the solid support to generate multiple pull-down complexes. (d) separating the plurality of pull-down complexes; (e) optionally eluting the plurality of adaptor-target polynucleotides from the plurality of pull-down complexes; (f) contacting the plurality of pull-down complexes or the plurality of eluted adaptor-target polynucleotides with a first polymerase under conditions that promote the generation of a plurality of complementary adaptor-target polynucleotides, wherein each of the complementary adaptor-target polynucleotides contains a 3' protecting group; (g) in the presence of a second ligase, contacting the plurality of adaptor-target polynucleotides with the plurality of sequencing adaptors under conditions that promote the ligation of a plurality of sequencing adaptors to the plurality of adaptor-target polynucleotides to generate a plurality of sequencing complexes; and (h) sequencing the plurality of sequencing complexes, wherein the sequencing includes sequencing the plurality of target polynucleotide sequences without sequencing the plurality of complementary adaptor-target polynucleotides, thereby detecting a plurality of base modifications in the plurality of target polynucleotides.

[0168] Implementation Scheme 5. A method for sequencing a plurality of target polynucleotides, the method comprising: (a) contacting the plurality of target polynucleotides with the one or more insulators in the presence of a first ligase, under conditions that promote the ligation of one or more insulators to the plurality of target polynucleotides to generate a plurality of insulator-target polynucleotides, wherein the one or more insulators contain primer binding sites; (b) contacting the plurality of insulator-target polynucleotides with the one or more tags in the condition that promotes hybridization of one or more tags to the plurality of insulator-target polynucleotides to generate a plurality of tagged insulator-target polynucleotides, wherein the one or more tags are complementary to one or more regions of the plurality of target polynucleotides; (c) contacting the plurality of tagged insulator-target polynucleotides with a solid support in the condition that promotes hybridization of the one or more tags to the solid support to generate a plurality of pull-down complexes; (d) separating the plurality of pull-down complexes. (e) optionally eluting the plurality of pull-down complexes from the plurality of adaptor-target polynucleotides; (f) contacting the plurality of pull-down complexes or the plurality of eluted adaptor-target polynucleotides with a first polymerase under conditions that promote the generation of a plurality of complementary adaptor-target polynucleotides, wherein each of the complementary adaptor-target polynucleotides contains a 3' protecting group; (g) in the presence of a second ligase, contacting the plurality of adaptor-target polynucleotides with the plurality of sequencing adaptors under conditions that promote the ligation of a plurality of sequencing adaptors to the plurality of adaptor-target polynucleotides to generate a plurality of sequencing complexes; and (h) sequencing the plurality of sequencing complexes, wherein the sequencing includes sequencing the plurality of target polynucleotide sequences without sequencing the plurality of complementary adaptor-target polynucleotides, thereby sequencing the plurality of target polynucleotides, wherein optionally the plurality of target polynucleotides contains one or more base modifications.

[0169] Implementation Scheme 6. A method for detecting multiple base modifications in a target polynucleotide, the method comprising: (a) contacting the target polynucleotide with the one or more intransitive protons in the presence of a first ligase to generate an intransitive-target polynucleotide, wherein the one or more intransitive protons contain a primer binding site; (b) contacting the intransitive-target polynucleotide with the one or more tags to generate a tagged intransitive-target polynucleotide, wherein the one or more tags are complementary to one or more regions of the target polynucleotide; and (c) contacting the tagged intransitive-target polynucleotide with a solid support to generate an intransitive-target polynucleotide. (d) generating a pull-down complex; (e) isolating the pull-down complex; (f) optionally eluting the adaptor-target polynucleotide from the pull-down complex; (g) contacting the pull-down complex or the eluted adaptor-target polynucleotide with a first polymerase under conditions that promote the generation of a complementary adaptor-target polynucleotide, wherein the complementary adaptor-target polynucleotide contains a 3' protecting group; (g) contacting the adaptor-target polynucleotide with the sequencing adaptor in the presence of a second ligase under conditions that promote the ligation of the sequencing adaptor to the adaptor-target polynucleotide to generate a sequencing complex; and (h) sequencing the sequencing complex, wherein the sequencing includes sequencing the target polynucleotide sequence without sequencing the complementary adaptor-target polynucleotide, thereby detecting the plurality of base modifications in the target polynucleotide.

[0170] Implementation Scheme 7. A method for detecting base modifications in a plurality of target polynucleotides, the method comprising: (a) in the presence of a first ligase, contacting the plurality of target polynucleotides with the one or more initiators under conditions that promote the ligation of one or more initiators to the plurality of target polynucleotides to generate a plurality of initiator-target polynucleotides, wherein the one or more initiators contain a primer binding site; (b) contacting the plurality of initiator-target polynucleotides with the one or more tags under conditions that promote the hybridization of one or more tags to the plurality of initiator-target polynucleotides to generate a plurality of tagged initiator-target polynucleotides, wherein the one or more tags are complementary to one or more regions of the plurality of target polynucleotides; (c) contacting the plurality of tagged initiator-target polynucleotides with the solid support under conditions that promote the hybridization of the one or more tags to the solid support to generate a plurality of pull-down complexes. (d) separating the plurality of pull-down complexes; (e) optionally eluting the plurality of adaptor-target polynucleotides from the plurality of pull-down complexes; (f) contacting the plurality of pull-down complexes or the plurality of eluted adaptor-target polynucleotides with a first polymerase under conditions that promote the generation of a plurality of complementary adaptor-target polynucleotides, wherein each of the complementary adaptor-target polynucleotides contains a 3' protecting group; (g) in the presence of a second ligase, contacting the plurality of adaptor-target polynucleotides with the plurality of sequencing adaptors under conditions that promote the ligation of a plurality of sequencing adaptors to the plurality of adaptor-target polynucleotides to generate a plurality of sequencing complexes; and (h) sequencing the plurality of sequencing complexes, wherein the sequencing includes sequencing the plurality of target polynucleotide sequences without sequencing the plurality of complementary adaptor-target polynucleotides, thereby detecting base modifications in the plurality of target polynucleotides.

[0171] Implementation Scheme 8. The method as described in any one of the above implementation schemes, further comprising: (i) analyzing the sequenced sequencing complex to detect the base modification.

[0172] Implementation Scheme 9. The method as described in any of the above implementation schemes, wherein the sequencing includes identifying base modifications in the target polynucleotide.

[0173] Implementation Scheme 10. The method as described in any of the above implementation schemes, further comprising using one or more additional connectors to repeat steps (a) to (i) at least once.

[0174] Implementation Scheme 11. The method as described in any of the above implementation schemes, wherein the target polynucleotide is isolated from the biological sample prior to step (a).

[0175] Implementation Scheme 12. The method as described in Implementation Scheme 11, wherein the biological sample is derived from a human.

[0176] Implementation Scheme 13. The method of any one of the above embodiments, wherein the target polynucleotide comprises genomic DNA (gDNA) or cell-free DNA (cfDNA).

[0177] Implementation Scheme 14. The method as described in any of the above implementation schemes, wherein the target polynucleotide is fragmented prior to step (a).

[0178] Implementation Scheme 15. The method as described in any of the above implementation schemes, wherein the one or more connectors further comprises a first barcode.

[0179] Implementation Scheme 16. The method of Implementation Scheme 15, wherein the one or more additional connectors further comprises one or more additional barcodes.

[0180] Implementation Scheme 17. The method as described in any of the above implementation schemes, wherein the one or more tags comprise streptavidin, biotin, maltose, maltose-binding protein, glutathione, glutathione S-transferase, chitin, chitin-binding protein, aptamer, antigen, SpyCatcher, SpyTag, or antibody.

[0181] Implementation Scheme 18. The method as described in any of the above implementation schemes, wherein the one or more tags target the same region of the target polynucleotide.

[0182] Implementation Scheme 19. The method of any one of Implementation Schemes 1 to 17, wherein the one or more tags target different regions of the target polynucleotide.

[0183] Implementation Scheme 20. The method of any one of the above implementation schemes, wherein the solid support comprises streptavidin, biotin, maltose, maltose-binding protein, glutathione, glutathione S-transferase, chitin, chitin-binding protein, aptamer, antigen, SpyCatcher, SpyTag, or antibody.

[0184] Implementation Scheme 21. The method as described in any of the above implementation schemes, wherein the solid support is a bead or a column.

[0185] Implementation Scheme 22. The method as described in Implementation Scheme 21, wherein the beads are paramagnetic.

[0186] Implementation Scheme 23. The method as described in any of the above implementation schemes, wherein the elution in step (e) comprises NaOH, heat, chain displacement polymerase or polymerase having exonuclease activity.

[0187] Implementation Scheme 24. The method as described in any of the above implementation schemes, wherein the 3' protecting group prevents sequencing of the complementary adaptor-target polynucleotide.

[0188] Implementation Scheme 25. The method as described in any of the above implementation schemes, wherein the 3' protecting group comprises a nucleotide overhang.

[0189] Implementation Scheme 26. The method of Implementation Scheme 25, wherein the nucleotide overhang comprises at least one nucleotide, two nucleotides, or three nucleotides.

[0190] Implementation Scheme 27. The method as described in any of the above implementation schemes, wherein the primers do not contain a 5' phosphate group.

[0191] Implementation Scheme 28. The method as described in any of the above implementation schemes, wherein the sequencing adaptor comprises a second barcode.

[0192] Implementation Scheme 29. The method of any one of the above embodiments, wherein the base modification includes 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), N6-methyladenine (6mA), 7-methylguanine (m7G), 2'-O-methylation (2'-O-methyl) or bromodeoxyuridine (BrdU).

[0193] Implementation Scheme 30. The method as described in any of the above implementation schemes, wherein the method does not include bisulfite conversion or amplification of the target polynucleotide.

[0194] Implementation Scheme 31. The method as described in any of the above implementation schemes, wherein the method does not include simplified representative bisulfite sequencing (RRBS) or simplified representative methylation sequencing (RRMS).

[0195] Implementation Scheme 32. The method as described in any of the above embodiments, wherein the first ligase or the second ligase is a T4 DNA ligase, a rapid ligase, a T3 ligase, a T7 ligase, or a tag ligase.

[0196] Implementation Scheme 33. The method as described in any of the above implementation schemes, wherein the first polymerase is Taq polymerase, BST polymerase, sulfur fern polymerase, thermominator polymerase, Kleno polymerase, or deep vent polymerase.

[0197] Implementation Scheme 34. The method as described in any of the above implementation schemes, wherein sequencing is performed on a sequencer capable of identifying the modified bases.

[0198] Implementation Scheme 35. The method as described in any of the above implementation schemes, wherein the base modification in the target polynucleotide is preserved until sequencing.

[0199] Implementation Scheme 36. The method as described in any of the above implementation schemes, wherein the method enriches the base modification in the target polynucleotide by about 300-fold to about 2400-fold compared to whole genome sequencing.

Claims

1. A method for detecting base modifications in a target polynucleotide, the method comprising: (a) In the presence of a first ligase, the target polynucleotide is contacted with the one or more initiators to generate an initiator-target polynucleotide under conditions that promote the ligation of one or more initiators to the target polynucleotide, wherein the one or more initiators contain a primer binding site. (b) Under conditions that promote hybridization of one or more tags with the adaptor-target polynucleotide, the adaptor-target polynucleotide is contacted with the one or more tags to produce a tagged adaptor-target polynucleotide, wherein the one or more tags are complementary to one or more regions of the target polynucleotide; (c) Under conditions that promote hybridization of the one or more tags with the solid support, the tagged adaptor-target polynucleotide is contacted with the solid support to generate a pull-down complex; (d) Separate the pull-down complex; (e) Optionally, the adaptor-target polynucleotide is eluted from the pull-down complex; (f) Under conditions that promote the production of complementary adaptor-target polynucleotides, the pull-down complex or the eluted adaptor-target polynucleotide is contacted with a first polymerase, wherein the complementary adaptor-target polynucleotide contains a 3' protecting group or a 5' protecting group. (g) In the presence of a second ligase, under conditions that promote the ligation of the sequencing adaptor to the adaptor-target polynucleotide, the adaptor-target polynucleotide is contacted with the sequencing adaptor to generate a sequencing complex; and (h) Sequencing the sequencing complex, wherein the sequencing includes sequencing the target polynucleotide sequence but not the complementary adaptor-target polynucleotide. This allows for the detection of the base modifications in the target polynucleotide.

2. A method for sequencing a target polynucleotide, the method comprising: (a) In the presence of a first ligase, the target polynucleotide is contacted with the one or more initiators to generate an initiator-target polynucleotide under conditions that promote the ligation of one or more initiators to the target polynucleotide, wherein the one or more initiators contain a primer binding site. (b) Under conditions that promote hybridization of one or more tags with the adaptor-target polynucleotide, the adaptor-target polynucleotide is contacted with the one or more tags to produce a tagged adaptor-target polynucleotide, wherein the one or more tags are complementary to one or more regions of the target polynucleotide; (c) Under conditions that promote hybridization of the one or more tags with the solid support, the tagged adaptor-target polynucleotide is contacted with the solid support to generate a pull-down complex; (d) Separate the pull-down complex; (e) Optionally, the adaptor-target polynucleotide is eluted from the pull-down complex; (f) Under conditions that promote the production of complementary adaptor-target polynucleotides, the pull-down complex or the eluted adaptor-target polynucleotide is contacted with a first polymerase, wherein the complementary adaptor-target polynucleotide contains a 3' protecting group or a 5' protecting group. (g) In the presence of a second ligase, under conditions that promote the ligation of the sequencing adaptor to the adaptor-target polynucleotide, the adaptor-target polynucleotide is contacted with the sequencing adaptor to generate a sequencing complex; and (h) Sequencing the sequencing complex, wherein the sequencing includes sequencing the target polynucleotide sequence but not the complementary adaptor-target polynucleotide. The target polynucleotide is then sequenced, optionally wherein the target polynucleotide contains one or more base modifications.

3. A method for quantifying base modifications in target polynucleotides, the method comprising: (a) In the presence of a first ligase, the target polynucleotide is contacted with the one or more initiators to generate an initiator-target polynucleotide under conditions that promote the ligation of one or more initiators to the target polynucleotide, wherein the one or more initiators contain a primer binding site. (b) Under conditions that promote hybridization of one or more tags with the adaptor-target polynucleotide or the adaptor-target polynucleotide with the one or more tags, the adaptor-target polynucleotide is contacted with the one or more tags to produce a tagged adaptor-target polynucleotide, wherein the one or more tags are complementary to one or more regions of the target polynucleotide; (c) Under conditions that promote hybridization of the one or more tags with the solid support, the tagged adaptor-target polynucleotide is contacted with the solid support to generate a pull-down complex; (d) Separate the pull-down complex; (e) Optionally, the adaptor-target polynucleotide is eluted from the pull-down complex; (f) Under conditions that promote the production of complementary adaptor-target polynucleotides, the pull-down complex or the eluted adaptor-target polynucleotide is contacted with a first polymerase, wherein the complementary adaptor-target polynucleotide contains a 3' protecting group or a 5' protecting group. (g) In the presence of a second ligase, under conditions that promote the ligation of the sequencing adaptor to the adaptor-target polynucleotide, the adaptor-target polynucleotide is contacted with the sequencing adaptor to generate a sequencing complex; and (h) Sequencing the sequencing complex, wherein the sequencing includes sequencing the target polynucleotide sequence but not the complementary adaptor-target polynucleotide. This allows for the quantification of the base modifications in the target polynucleotide.

4. A method for detecting multiple base modifications in multiple target polynucleotides, the method comprising: (a) In the presence of a first ligase, the plurality of target polynucleotides are contacted with the one or more initiators to generate a plurality of initiator-target polynucleotides, wherein the one or more initiators contain a primer binding site. (b) Under conditions that promote hybridization of one or more tags with the plurality of adaptor-target polynucleotides, the plurality of adaptor-target polynucleotides are contacted with the one or more tags to generate a plurality of tagged adaptor-target polynucleotides, wherein the one or more tags are complementary to one or more regions of the plurality of target polynucleotides; (c) Under conditions that promote hybridization of the one or more tags with the solid support, the plurality of tagged adaptor-target polynucleotides are contacted with the solid support to generate a plurality of pull-down complexes; (d) Separate the plurality of pull-down complexes; (e) Optionally, the plurality of adaptor-target polynucleotides are eluted from the plurality of pull-down complexes; (f) Under conditions that promote the production of multiple complementary adaptor-target polynucleotides, the multiple pull-down complexes or multiple eluted adaptor-target polynucleotides are contacted with a first polymerase, wherein each of the complementary adaptor-target polynucleotides contains a 3' protecting group or a 5' protecting group. (g) In the presence of a second ligase, under conditions that promote the ligation of multiple sequencing adaptors to the multiple adaptor-target polynucleotides, the multiple adaptor-target polynucleotides are contacted with the multiple sequencing adaptors to generate multiple sequencing complexes; and (h) Sequencing the plurality of sequencing complexes, wherein the sequencing includes sequencing the plurality of target polynucleotide sequences but not the plurality of complementary adaptor-target polynucleotides. This allows for the detection of multiple base modifications in the multiple target polynucleotides.

5. A method for sequencing multiple target polynucleotides, the method comprising: (a) In the presence of a first ligase, the plurality of target polynucleotides are contacted with the one or more initiators to generate a plurality of initiator-target polynucleotides, wherein the one or more initiators contain a primer binding site. (b) Under conditions that promote hybridization of one or more tags with the plurality of adaptor-target polynucleotides, the plurality of adaptor-target polynucleotides are contacted with the one or more tags to generate a plurality of tagged adaptor-target polynucleotides, wherein the one or more tags are complementary to one or more regions of the plurality of target polynucleotides; (c) Under conditions that promote hybridization of the one or more tags with the solid support, the plurality of tagged adaptor-target polynucleotides are contacted with the solid support to generate a plurality of pull-down complexes; (d) Separate the plurality of pull-down complexes; (e) Optionally, the plurality of adaptor-target polynucleotides are eluted from the plurality of pull-down complexes; (f) Under conditions that promote the production of multiple complementary adaptor-target polynucleotides, the multiple pull-down complexes or multiple eluted adaptor-target polynucleotides are contacted with a first polymerase, wherein each of the complementary adaptor-target polynucleotides contains a 3' protecting group or a 5' protecting group. (g) In the presence of a second ligase, under conditions that promote the ligation of multiple sequencing adaptors to the multiple adaptor-target polynucleotides, the multiple adaptor-target polynucleotides are contacted with the multiple sequencing adaptors to generate multiple sequencing complexes; and (h) Sequencing the plurality of sequencing complexes, wherein the sequencing includes sequencing the plurality of target polynucleotide sequences but not the plurality of complementary adaptor-target polynucleotides. The plurality of target polynucleotides are then sequenced, wherein optionally the plurality of target polynucleotides contain one or more base modifications.

6. A method for detecting multiple base modifications in a target polynucleotide, the method comprising: (a) In the presence of a first ligase, the target polynucleotide is contacted with the one or more initiators to generate an initiator-target polynucleotide under conditions that promote the ligation of one or more initiators to the target polynucleotide, wherein the one or more initiators contain a primer binding site. (b) Under conditions that promote hybridization of one or more tags with the adaptor-target polynucleotide, the adaptor-target polynucleotide is contacted with the one or more tags to produce a tagged adaptor-target polynucleotide, wherein the one or more tags are complementary to one or more regions of the target polynucleotide; (c) Under conditions that promote hybridization of the one or more tags with the solid support, the tagged adaptor-target polynucleotide is contacted with the solid support to generate a pull-down complex; (d) Separate the pull-down complex; (e) Optionally, the adaptor-target polynucleotide is eluted from the pull-down complex; (f) Under conditions that promote the production of complementary adaptor-target polynucleotides, the pull-down complex or the eluted adaptor-target polynucleotide is contacted with a first polymerase, wherein the complementary adaptor-target polynucleotide contains a 3' protecting group or a 5' protecting group. (g) In the presence of a second ligase, under conditions that promote the ligation of the sequencing adaptor to the adaptor-target polynucleotide, the adaptor-target polynucleotide is contacted with the sequencing adaptor to generate a sequencing complex; and (h) Sequencing the sequencing complex, wherein the sequencing includes sequencing the target polynucleotide sequence but not the complementary adaptor-target polynucleotide. This allows for the detection of the multiple base modifications in the target polynucleotide.

7. A method for detecting base modifications in multiple target polynucleotides, the method comprising: (a) In the presence of a first ligase, the plurality of target polynucleotides are contacted with the one or more initiators to generate a plurality of initiator-target polynucleotides, wherein the one or more initiators contain a primer binding site. (b) Under conditions that promote hybridization of one or more tags with the plurality of adaptor-target polynucleotides, the plurality of adaptor-target polynucleotides are contacted with the one or more tags to generate a plurality of tagged adaptor-target polynucleotides, wherein the one or more tags are complementary to one or more regions of the plurality of target polynucleotides; (c) Under conditions that promote hybridization of the one or more tags with the solid support, the plurality of tagged adaptor-target polynucleotides are contacted with the solid support to generate a plurality of pull-down complexes; (d) Separate the plurality of pull-down complexes; (e) Optionally, the plurality of adaptor-target polynucleotides are eluted from the plurality of pull-down complexes; (f) Under conditions that promote the production of multiple complementary adaptor-target polynucleotides, the multiple pull-down complexes or multiple eluted adaptor-target polynucleotides are contacted with a first polymerase, wherein each of the complementary adaptor-target polynucleotides contains a 3' protecting group or a 5' protecting group. (g) In the presence of a second ligase, under conditions that promote the ligation of multiple sequencing adaptors to the multiple adaptor-target polynucleotides, the multiple adaptor-target polynucleotides are contacted with the multiple sequencing adaptors to generate multiple sequencing complexes; and (h) Sequencing the plurality of sequencing complexes, wherein the sequencing includes sequencing the plurality of target polynucleotide sequences but not the plurality of complementary adaptor-target polynucleotides. This allows for the detection of base modifications in the multiple target polynucleotides.

8. The method as described in any one of the preceding claims, further comprising: (i) Analyze the sequenced sequencing complex to detect the base modifications.

9. The method of any of the preceding claims, wherein the sequencing comprises identifying base modifications in the target polynucleotide.

10. The method as claimed in any of the preceding claims, further comprising using one or more additional connectors to repeat steps (a) to (i) at least once.

11. The method as claimed in any of the preceding claims, wherein the target polynucleotide is isolated from the biological sample prior to step (a).

12. The method of claim 11, wherein the biological sample is derived from a human.

13. The method of any of the preceding claims, wherein the target polynucleotide comprises genomic DNA (gDNA) or cell-free DNA (cfDNA).

14. The method of any of the preceding claims, wherein the target polynucleotide is fragmented prior to step (a).

15. The method of any of the preceding claims, wherein the one or more connectors further comprises a first barcode.

16. The method of claim 15, wherein the one or more additional connectors further comprise one or more additional barcodes.

17. The method of any of the preceding claims, wherein the one or more tags comprise streptavidin, biotin, maltose, maltose-binding protein, glutathione, glutathione S-transferase, chitin, chitin-binding protein, aptamer, antigen, SpyCatcher, SpyTag, or antibody.

18. The method of any of the preceding claims, wherein the one or more tags target the same region of the target polynucleotide.

19. The method of any one of claims 1 to 17, wherein the one or more tags target different regions of the target polynucleotide.

20. The method of any of the preceding claims, wherein the solid support comprises streptavidin, biotin, maltose, maltose-binding protein, glutathione, glutathione S-transferase, chitin, chitin-binding protein, aptamer, antigen, SpyCatcher, SpyTag, or antibody.

21. The method of any of the preceding claims, wherein the solid support is a bead or a column.

22. The method of claim 21, wherein the beads are paramagnetic.

23. The method as claimed in any of the preceding claims, wherein the elution in step (e) comprises NaOH, heat, chain displacement polymerase or a polymerase having exonuclease activity.

24. The method of any of the preceding claims, wherein the 3' protecting group or the 5' protecting group prevents sequencing of the complementary adaptor-target polynucleotide.

25. The method of any of the preceding claims, wherein the 3' protecting group comprises a nucleotide overhang.

26. The method of claim 25, wherein the nucleotide overhang comprises at least one nucleotide, two nucleotides, or three nucleotides.

27. The method as described in any of the preceding claims, wherein the primer does not contain a 5' phosphate group.

28. The method of any of the preceding claims, wherein the sequencing adaptor comprises a second barcode.

29. The method of any of the preceding claims, wherein the base modification comprises 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), N, 6-methyladenine (6mA), 7-methylguanine (m7G), 2'-O-methylation (2'-O-methyl) or bromodeoxyuridine (BrdU).

30. The method of any of the preceding claims, wherein the method does not include bisulfite conversion or amplification of the target polynucleotide.

31. The method as claimed in any of the preceding claims, wherein the method does not include simplified representative bisulfite sequencing (RRBS) or simplified representative methylation sequencing (RRMS).

32. The method of any of the preceding claims, wherein the first ligase or the second ligase is a T4 DNA ligase, a fast ligase, a T3 ligase, a T7 ligase, or a tag ligase.

33. The method of any of the preceding claims, wherein the first polymerase is Taq polymerase, BST polymerase, sulfur fern polymerase, thermominator polymerase, Kleno polymerase, or deep vent polymerase.

34. The method of any of the preceding claims, wherein sequencing is performed on a sequencer capable of identifying the modified bases.

35. The method of any of the preceding claims, wherein the base modification in the target polynucleotide is retained until sequencing.

36. The method of any of the preceding claims, wherein the method enriches the base modification in the target polynucleotide by about 300-fold to about 2400-fold compared to whole-genome sequencing.